{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T16:53:54Z","timestamp":1787331234547,"version":"build-2736575974"},"reference-count":292,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-026-06021-5","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:35:20Z","timestamp":1782434120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting GPCR Signaling in Parkinson\u2019s Disease: From Molecular Pathology to Exercise-Based Therapeutics"],"prefix":"10.1007","volume":"63","author":[{"given":"Boyi","family":"Zong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengzhi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yige","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8002-6563","authenticated-orcid":false,"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"10423","key":"6021_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM, Williams-Gray CH (2024) The pathogenesis of Parkinson\u2019s disease. Lancet 403(10423):293\u2013304. https:\/\/doi.org\/10.1016\/S0140-6736(23)01478-2","journal-title":"Lancet"},{"key":"6021_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080952","volume":"388","author":"D Su","year":"2025","unstructured":"Su D, Cui Y, He C, Yin P, Bai R, Zhu J, Lam JST, Zhang J et al (2025) Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of global burden of disease study 2021. BMJ 388:e080952. https:\/\/doi.org\/10.1136\/bmj-2024-080952","journal-title":"BMJ"},{"issue":"1","key":"6021_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1474-4422(21)00330-6","volume":"21","author":"D Weintraub","year":"2022","unstructured":"Weintraub D, Aarsland D, Chaudhuri KR, Dobkin RD, Leentjens AF, Rodriguez-Violante M, Schrag A (2022) The neuropsychiatry of Parkinson\u2019s disease: advances and challenges. Lancet Neurol 21(1):89\u2013102. https:\/\/doi.org\/10.1016\/S1474-4422(21)00330-6","journal-title":"Lancet Neurol"},{"key":"6021_CR4","doi-asserted-by":"publisher","unstructured":"Belloso-Iguerategui A, Zamarbide M, Merino-Galan L, Rodriguez-Chinchilla T, Gago B, Santamaria E, Fernandez-Irigoyen J, Cotman CW et al (2023) Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit. Brain 146(12):4949\u20134963. https:\/\/doi.org\/10.1093\/brain\/awad227","DOI":"10.1093\/brain\/awad227"},{"issue":"11","key":"6021_CR5","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1093\/brain\/awab242","volume":"144","author":"A Tozzi","year":"2021","unstructured":"Tozzi A, Sciaccaluga M, Loffredo V, Megaro A, Ledonne A, Cardinale A, Federici M, Bellingacci L et al (2021) Dopamine-dependent early synaptic and motor dysfunctions induced by \u03b1-synuclein in the nigrostriatal circuit. Brain 144(11):3477\u20133491. https:\/\/doi.org\/10.1093\/brain\/awab242","journal-title":"Brain"},{"key":"6021_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1146\/annurev-neuro-100720-034518","volume":"44","author":"GE Vazquez-Velez","year":"2021","unstructured":"Vazquez-Velez GE, Zoghbi HY (2021) Parkinson\u2019s disease genetics and pathophysiology. Annu Rev Neurosci 44:87\u2013108. https:\/\/doi.org\/10.1146\/annurev-neuro-100720-034518","journal-title":"Annu Rev Neurosci"},{"issue":"11","key":"6021_CR7","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.it.2022.09.010","volume":"43","author":"G Lawrence","year":"2022","unstructured":"Lawrence G, Holley CL, Schroder K (2022) Parkinson\u2019s disease: connecting mitochondria to inflammasomes. Trends Immunol 43(11):877\u2013885. https:\/\/doi.org\/10.1016\/j.it.2022.09.010","journal-title":"Trends Immunol"},{"key":"6021_CR8","doi-asserted-by":"publisher","unstructured":"Ding XS, Gao L, Han Z, Eleuteri S, Shi W, Shen Y, Song ZY, Su M et al (2023) Ferroptosis in Parkinson\u2019s disease: molecular mechanisms and therapeutic potential. Ageing Res Rev 91:102077. https:\/\/doi.org\/10.1016\/j.arr.2023.102077","DOI":"10.1016\/j.arr.2023.102077"},{"issue":"10","key":"6021_CR9","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1016\/j.ymthe.2021.06.005","volume":"29","author":"Y Itokazu","year":"2021","unstructured":"Itokazu Y, Fuchigami T, Morgan JC, Yu RK (2021) Intranasal infusion of GD3 and GM1 gangliosides downregulates alpha-synuclein and controls tyrosine hydroxylase gene in a PD model mouse. Mol Ther 29(10):3059\u20133071. https:\/\/doi.org\/10.1016\/j.ymthe.2021.06.005","journal-title":"Mol Ther"},{"issue":"1","key":"6021_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s12951-024-02587-1","volume":"22","author":"T Lei","year":"2024","unstructured":"Lei T, Li C, Liu Y, Cui Z, Deng S, Cao J, Yang H, Chen P (2024) Microfluidics-enabled mesenchymal stem cell derived neuron like cell membrane coated nanoparticles inhibit inflammation and apoptosis for Parkinson\u2019s disease. J Nanobiotechnology 22(1):370. https:\/\/doi.org\/10.1186\/s12951-024-02587-1","journal-title":"J Nanobiotechnology"},{"key":"6021_CR11","doi-asserted-by":"publisher","unstructured":"Sul JH, Shin S, Kim HK, Han J, Kim J, Son S, Lee J, Baek SH et al (2024) Dopamine-conjugated extracellular vesicles induce autophagy in Parkinson\u2019s disease. J Extracell Vesicles 13(12):e70018. https:\/\/doi.org\/10.1002\/jev2.70018","DOI":"10.1002\/jev2.70018"},{"issue":"1","key":"6021_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12974-022-02496-w","volume":"19","author":"A Heidari","year":"2022","unstructured":"Heidari A, Yazdanpanah N, Rezaei N (2022) The role of Toll-like receptors and neuroinflammation in Parkinson\u2019s disease. J Neuroinflammation 19(1):135. https:\/\/doi.org\/10.1186\/s12974-022-02496-w","journal-title":"J Neuroinflammation"},{"issue":"7","key":"6021_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","volume":"20","author":"N Vijiaratnam","year":"2021","unstructured":"Vijiaratnam N, Simuni T, Bandmann O, Morris HR, Foltynie T (2021) Progress towards therapies for disease modification in Parkinson\u2019s disease. Lancet Neurol 20(7):559\u2013572. https:\/\/doi.org\/10.1016\/S1474-4422(21)00061-2","journal-title":"Lancet Neurol"},{"issue":"11","key":"6021_CR14","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1136\/jnnp-2023-332974","volume":"95","author":"M Langeskov-Christensen","year":"2024","unstructured":"Langeskov-Christensen M, Franzen E, Grondahl Hvid L, Dalgas U (2024) Exercise as medicine in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 95(11):1077\u20131088. https:\/\/doi.org\/10.1136\/jnnp-2023-332974","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6021_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102147","volume":"93","author":"J Burtscher","year":"2024","unstructured":"Burtscher J, Moraud EM, Malatesta D, Millet GP, Bally JF, Patoz A (2024) Exercise and gait\/movement analyses in treatment and diagnosis of Parkinson\u2019s disease. Ageing Res Rev 93:102147. https:\/\/doi.org\/10.1016\/j.arr.2023.102147","journal-title":"Ageing Res Rev"},{"key":"6021_CR16","doi-asserted-by":"publisher","unstructured":"Vieira de Moraes Filho A, Chaves SN, Martins WR, Tolentino GP, de Cassia Pereira Pinto Homem R, Landim de Farias G, Fischer BL, Oliveira JA et al (2020) Progressive resistance training improves bradykinesia, motor symptoms and functional performance in patients with Parkinson\u2019s disease. Clin Interv Aging 15:87\u201395. https:\/\/doi.org\/10.2147\/CIA.S231359","DOI":"10.2147\/CIA.S231359"},{"key":"6021_CR17","doi-asserted-by":"publisher","unstructured":"Dhamija RK, Saluja A, Garg D, Chauhan S, Majumdar R, Bhardwaj SB, Preenja R, Kashyap D et al (2025) Teleneurorehabilitation and motor and nonmotor symptoms and quality of life in Parkinson disease: the TELEPARK randomized clinical trial. JAMA Neurol 82(4):376\u2013383. https:\/\/doi.org\/10.1001\/jamaneurol.2024.5387","DOI":"10.1001\/jamaneurol.2024.5387"},{"key":"6021_CR18","doi-asserted-by":"publisher","unstructured":"Conflitti P, Lyman E, Sansom MSP, Hildebrand PW, Gutierrez-de-Teran H, Carloni P, Ansell TB, Yuan S et al (2025) Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery. Nat Rev Drug Discov 24(4):251\u2013275. https:\/\/doi.org\/10.1038\/s41573-024-01083-3","DOI":"10.1038\/s41573-024-01083-3"},{"issue":"4","key":"6021_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1124\/pr.119.018044","volume":"71","author":"HA Dunn","year":"2019","unstructured":"Dunn HA, Orlandi C, Martemyanov KA (2019) Beyond the ligand: extracellular and transcellular G protein-coupled receptor complexes in physiology and pharmacology. Pharmacol Rev 71(4):503\u2013519. https:\/\/doi.org\/10.1124\/pr.119.018044","journal-title":"Pharmacol Rev"},{"issue":"7","key":"6021_CR20","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/s12276-025-01497-y","volume":"57","author":"J Kim","year":"2025","unstructured":"Kim J, Kim J, Choi C, Bae J, Choi HJ (2025) Structural insights into GPCR signaling activated by peptide ligands: from molecular mechanism to therapeutic application. Exp Mol Med 57(7):1467\u20131481. https:\/\/doi.org\/10.1038\/s12276-025-01497-y","journal-title":"Exp Mol Med"},{"issue":"10","key":"6021_CR21","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41580-018-0049-3","volume":"19","author":"D Wootten","year":"2018","unstructured":"Wootten D, Christopoulos A, Marti-Solano M, Babu MM, Sexton PM (2018) Mechanisms of signalling and biased agonism in G protein-coupled receptors. Nat Rev Mol Cell Biol 19(10):638\u2013653. https:\/\/doi.org\/10.1038\/s41580-018-0049-3","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"6021_CR22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrd.2018.135","volume":"17","author":"AP Campbell","year":"2018","unstructured":"Campbell AP, Smrcka AV (2018) Targeting G protein-coupled receptor signalling by blocking G proteins. Nat Rev Drug Discov 17(11):789\u2013803. https:\/\/doi.org\/10.1038\/nrd.2018.135","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"6021_CR23","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41581-024-00869-3","volume":"20","author":"AD Toth","year":"2024","unstructured":"Toth AD, Turu G, Hunyady L (2024) Functional consequences of spatial, temporal and ligand bias of G protein-coupled receptors. Nat Rev Nephrol 20(11):722\u2013741. https:\/\/doi.org\/10.1038\/s41581-024-00869-3","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"6021_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cells10030709","volume":"10","author":"BM Roberts","year":"2021","unstructured":"Roberts BM, Lopes EF, Cragg SJ (2021) Axonal modulation of striatal dopamine release by local \u03b3-aminobutyric acid (GABA) signalling. Cells 10(3):709. https:\/\/doi.org\/10.3390\/cells10030709","journal-title":"Cells"},{"key":"6021_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102200","volume":"94","author":"HM Al-Kuraishy","year":"2024","unstructured":"Al-Kuraishy HM, Al-Hamash SM, Jabir MS, Al-Gareeb AI, Albuhadily AK, Albukhaty S, Sulaiman GM (2024) The classical and non-classical axes of renin-angiotensin system in Parkinson disease: the bright and dark side of the moon. Ageing Res Rev 94:102200. https:\/\/doi.org\/10.1016\/j.arr.2024.102200","journal-title":"Ageing Res Rev"},{"key":"6021_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.109745","volume":"96","author":"QW Han","year":"2020","unstructured":"Han QW, Yuan YH, Chen NH (2020) The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson\u2019s disease. Prog Neuropsychopharmacol Biol Psychiatry 96:109745. https:\/\/doi.org\/10.1016\/j.pnpbp.2019.109745","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"6021_CR27","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41531-025-01138-1","volume":"11","author":"M Alborghetti","year":"2025","unstructured":"Alborghetti M, Ceccherelli A, Caridi M, Nicoletti F, Battaglia G, Bruno V (2025) Targeting metabotropic glutamate receptors for symptomatic and disease-modifying treatment in Parkinson\u2019s disease. NPJ Parkinsons Dis 11(1):290. https:\/\/doi.org\/10.1038\/s41531-025-01138-1","journal-title":"NPJ Parkinsons Dis"},{"key":"6021_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.pneurobio.2015.09.005","volume":"134","author":"Y Ohno","year":"2015","unstructured":"Ohno Y, Shimizu S, Tokudome K, Kunisawa N, Sasa M (2015) New insight into the therapeutic role of the serotonergic system in Parkinson\u2019s disease. Prog Neurobiol 134:104\u2013121. https:\/\/doi.org\/10.1016\/j.pneurobio.2015.09.005","journal-title":"Prog Neurobiol"},{"issue":"8","key":"6021_CR29","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","volume":"5","author":"CW Olanow","year":"2006","unstructured":"Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol 5(8):677\u2013687. https:\/\/doi.org\/10.1016\/S1474-4422(06)70521-X","journal-title":"Lancet Neurol"},{"issue":"6","key":"6021_CR30","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1007\/s12035-023-03257-3","volume":"60","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Liu X, Yang G (2023) Adenosinergic pathway in Parkinson\u2019s disease: recent advances and therapeutic perspective. Mol Neurobiol 60(6):3054\u20133070. https:\/\/doi.org\/10.1007\/s12035-023-03257-3","journal-title":"Mol Neurobiol"},{"key":"6021_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15557","volume":"8","author":"C Morland","year":"2017","unstructured":"Morland C, Andersson KA, Haugen OP, Hadzic A, Kleppa L, Gille A, Rinholm JE, Palibrk V et al (2017) Exercise induces cerebral VEGF and angiogenesis via the lactate receptor HCAR1. Nat Commun 8:15557. https:\/\/doi.org\/10.1038\/ncomms15557","journal-title":"Nat Commun"},{"issue":"1","key":"6021_CR32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41398-024-02877-0","volume":"14","author":"RS Rodrigues","year":"2024","unstructured":"Rodrigues RS, Moreira JB, Mateus JM, Barateiro A, Paulo SL, Vaz SH, Lourenco DM, Ribeiro FF et al (2024) Cannabinoid type 2 receptor inhibition enhances the antidepressant and proneurogenic effects of physical exercise after chronic stress. Transl Psychiatry 14(1):170. https:\/\/doi.org\/10.1038\/s41398-024-02877-0","journal-title":"Transl Psychiatry"},{"key":"6021_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.869507","volume":"14","author":"B Zong","year":"2022","unstructured":"Zong B, Yu F, Zhang X, Zhao W, Sun P, Li S, Li L (2022) Understanding how physical exercise improves Alzheimer\u2019s disease: cholinergic and monoaminergic systems. Front Aging Neurosci 14:869507. https:\/\/doi.org\/10.3389\/fnagi.2022.869507","journal-title":"Front Aging Neurosci"},{"key":"6021_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4103\/ijpvm.ijpvm_353_24","volume":"16","author":"AA Naser","year":"2025","unstructured":"Naser AA, Dehkordi KJ, Radhi MN, Taghian F, Chitsaz A (2025) The effect of multimodal exercise on the levels of BDNF and GDNF in patients with Parkinson\u2019s disease. Int J Prev Med 16:35. https:\/\/doi.org\/10.4103\/ijpvm.ijpvm_353_24","journal-title":"Int J Prev Med"},{"key":"6021_CR35","doi-asserted-by":"publisher","unstructured":"Rotondo R, Proietti S, Perluigi M, Padua E, Stocchi F, Fini M, Stocchi V, Volpe D et al (2023) Physical activity and neurotrophic factors as potential drivers of neuroplasticity in Parkinson\u2019s disease: a systematic review and meta-analysis. Ageing Res Rev 92:102089. https:\/\/doi.org\/10.1016\/j.arr.2023.102089","DOI":"10.1016\/j.arr.2023.102089"},{"issue":"23","key":"6021_CR36","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.1523\/JNEUROSCI.2273-21.2022","volume":"42","author":"G Bastioli","year":"2022","unstructured":"Bastioli G, Arnold JC, Mancini M, Mar AC, Gamallo-Lana B, Saadipour K, Chao MV, Rice ME (2022) Voluntary exercise boosts striatal dopamine release: evidence for the necessary and sufficient role of BDNF. J Neurosci 42(23):4725\u20134736. https:\/\/doi.org\/10.1523\/JNEUROSCI.2273-21.2022","journal-title":"J Neurosci"},{"issue":"4","key":"6021_CR37","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1007\/s12035-018-1278-3","volume":"56","author":"AE Speck","year":"2019","unstructured":"Speck AE, Schamne MG, S. Aguiar AJ, Cunha RA, Prediger RD (2019) Treadmill exercise attenuates L-DOPA-induced dyskinesia and increases striatal levels of glial cell-derived neurotrophic factor (GDNF) in hemiparkinsonian mice. Mol Neurobiol 56(4):2944\u20132951. https:\/\/doi.org\/10.1007\/s12035-018-1278-3","journal-title":"Mol Neurobiol"},{"issue":"4","key":"6021_CR38","doi-asserted-by":"publisher","first-page":"E734","DOI":"10.1152\/ajpendo.00071.2020","volume":"319","author":"XW Wang","year":"2020","unstructured":"Wang XW, Yuan LJ, Yang Y, Zhang M, Chen WF (2020) IGF-1 inhibits MPTP\/MPP(+)-induced autophagy on dopaminergic neurons through the IGF-1R\/PI3K-Akt-mTOR pathway and GPER. Am J Physiol Endocrinol Metab 319(4):E734\u2013E743. https:\/\/doi.org\/10.1152\/ajpendo.00071.2020","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"6021_CR39","doi-asserted-by":"publisher","first-page":"1352305","DOI":"10.3389\/fphys.2024.1352305","volume":"15","author":"A Paterno","year":"2024","unstructured":"Paterno A, Polsinelli G, Federico B (2024) Changes of brain-derived neurotrophic factor (BDNF) levels after different exercise protocols: a systematic review of clinical studies in Parkinson\u2019s disease. Front Physiol 15:1352305. https:\/\/doi.org\/10.3389\/fphys.2024.1352305","journal-title":"Front Physiol"},{"issue":"8","key":"6021_CR40","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s00429-023-02659-2","volume":"228","author":"Z Wang","year":"2023","unstructured":"Wang Z, Donahue EK, Guo Y, Renteln M, Petzinger GM, Jakowec MW, Holschneider DP (2023) Exercise alters cortico-basal ganglia network metabolic connectivity: a mesoscopic level analysis informed by anatomic parcellation defined in the mouse brain connectome. Brain Struct Funct 228(8):1865\u20131884. https:\/\/doi.org\/10.1007\/s00429-023-02659-2","journal-title":"Brain Struct Funct"},{"issue":"4","key":"6021_CR41","first-page":"547","volume":"71","author":"G Zhao","year":"2019","unstructured":"Zhao G, Zhang DY, Liu XL, Qiao DC (2019) Dopamine D2 receptor may be involved in the regulation of cortical-striatum synaptic transmission and autonomic activity in PD mice by exercise. Sheng Li Xue Bao 71(4):547\u2013554","journal-title":"Sheng Li Xue Bao"},{"key":"6021_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.680270","volume":"13","author":"T Szturm","year":"2021","unstructured":"Szturm T, Kolesar TA, Mahana B, Goertzen AL, Hobson DE, Marotta JJ, Strafella AP, Ko JH (2021) Changes in metabolic activity and gait function by dual-task cognitive game-based treadmill system in Parkinson\u2019s disease: protocol of a randomized controlled trial. Front Aging Neurosci 13:680270. https:\/\/doi.org\/10.3389\/fnagi.2021.680270","journal-title":"Front Aging Neurosci"},{"key":"6021_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2025.149540","volume":"1854","author":"D Kumar","year":"2025","unstructured":"Kumar D, Kumar R, Janrao S, Sharma V, Begum N, Fernandes V, Khatri DK (2025) Treadmill exercise mitigates rotenone-induced neuroinflammation and alpha-synuclein level in a mouse model of Parkinson\u2019s disease. Brain Res 1854:149540. https:\/\/doi.org\/10.1016\/j.brainres.2025.149540","journal-title":"Brain Res"},{"issue":"7","key":"6021_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/acel.70061","volume":"24","author":"R Zhao","year":"2025","unstructured":"Zhao R, Tian X, Xu H, Wang Y, Lin J, Wang B (2025) Aerobic exercise restores hippocampal neurogenesis and cognitive function by decreasing microglia inflammasome formation through irisin\/NLRP3 pathway. Aging Cell 24(7):e70061. https:\/\/doi.org\/10.1111\/acel.70061","journal-title":"Aging Cell"},{"issue":"1","key":"6021_CR45","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41531-025-01200-y","volume":"11","author":"L Baldauf","year":"2025","unstructured":"Baldauf L, Feja M, Stanojlovic M, Strowig T, Visscher C, Schaeffer E, Berg D, Hankel J et al (2025) Depending on intensity, exercise improved or worsened pathology in a model of prodromal Parkinson\u2019s disease. NPJ Parkinsons Dis 11(1):335. https:\/\/doi.org\/10.1038\/s41531-025-01200-y","journal-title":"NPJ Parkinsons Dis"},{"key":"6021_CR46","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.brainresbull.2021.06.024","volume":"174","author":"W Wang","year":"2021","unstructured":"Wang W, Lv Z, Gao J, Liu M, Wang Y, Tang C, Xiang J (2021) Treadmill exercise alleviates neuronal damage by suppressing NLRP3 inflammasome and microglial activation in the MPTP mouse model of Parkinson\u2019s disease. Brain Res Bull 174:349\u2013358. https:\/\/doi.org\/10.1016\/j.brainresbull.2021.06.024","journal-title":"Brain Res Bull"},{"issue":"3","key":"6021_CR47","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s12640-017-9770-5","volume":"32","author":"JH Koo","year":"2017","unstructured":"Koo JH, Cho JY (2017) Treadmill exercise attenuates alpha-synuclein levels by promoting mitochondrial function and autophagy possibly via SIRT1 in the chronic MPTP\/P-induced mouse model of Parkinson\u2019s disease. Neurotox Res 32(3):473\u2013486. https:\/\/doi.org\/10.1007\/s12640-017-9770-5","journal-title":"Neurotox Res"},{"issue":"5","key":"6021_CR48","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s12576-017-0586-0","volume":"68","author":"DJ Hwang","year":"2018","unstructured":"Hwang DJ, Koo JH, Kwon KC, Choi DH, Shin SD, Jeong JH, Um HS, Cho JY (2018) Neuroprotective effect of treadmill exercise possibly via regulation of lysosomal degradation molecules in mice with pharmacologically induced Parkinson\u2019s disease. J Physiol Sci 68(5):707\u2013716. https:\/\/doi.org\/10.1007\/s12576-017-0586-0","journal-title":"J Physiol Sci"},{"key":"6021_CR49","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.neuroscience.2018.03.015","volume":"379","author":"Y Jang","year":"2018","unstructured":"Jang Y, Kwon I, Song W, Cosio-Lima LM, Lee Y (2018) Endurance exercise mediates neuroprotection against MPTP-mediated Parkinson\u2019s disease via enhanced neurogenesis, antioxidant capacity, and autophagy. Neurosci 379:292\u2013301. https:\/\/doi.org\/10.1016\/j.neuroscience.2018.03.015","journal-title":"Neurosci"},{"issue":"2","key":"6021_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111058","volume":"40","author":"D Dutta","year":"2022","unstructured":"Dutta D, Paidi RK, Raha S, Roy A, Chandra S, Pahan K (2022) Treadmill exercise reduces alpha-synuclein spreading via PPARalpha. Cell Rep 40(2):111058. https:\/\/doi.org\/10.1016\/j.celrep.2022.111058","journal-title":"Cell Rep"},{"key":"6021_CR51","doi-asserted-by":"publisher","unstructured":"Xu J, He X, Li L, Zhang L, Li M, Mu Y, Yang X, Li S et al (2025) Voluntary exercise alleviates neural functional deficits in Parkinson\u2019s disease mice by inhibiting microglial ferroptosis via SLC7A11\/ALOX12 axis. NPJ Parkinsons Dis 11(1):55. https:\/\/doi.org\/10.1038\/s41531-025-00912-5","DOI":"10.1038\/s41531-025-00912-5"},{"issue":"2","key":"6021_CR52","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/mds.870080203","volume":"8","author":"JO Rinne","year":"1993","unstructured":"Rinne JO, Laihinen A, Rinne UK, Nagren K, Bergman J, Ruotsalainen U (1993) PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson\u2019s disease. Mov Disord 8(2):134\u2013138. https:\/\/doi.org\/10.1002\/mds.870080203","journal-title":"Mov Disord"},{"issue":"1","key":"6021_CR53","first-page":"65","volume":"41","author":"V Kaasinen","year":"2000","unstructured":"Kaasinen V, Ruottinen HM, Nagren K, Lehikoinen P, Oikonen V, Rinne JO (2000) Upregulation of putaminal dopamine D2 receptors in early Parkinson\u2019s disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. J Nucl Med 41(1):65\u201370","journal-title":"J Nucl Med"},{"issue":"1","key":"6021_CR54","doi-asserted-by":"publisher","first-page":"15943","DOI":"10.1038\/s41598-025-99580-x","volume":"15","author":"T Delgado-Goni","year":"2025","unstructured":"Delgado-Goni T, Connor-Robson N, Cioroch M, Paisey S, Marshall C, Lane EL, Hauton D, McCullagh J et al (2025) Dopamine D2 receptor upregulation in dorsal striatum in the LRRK2-R1441C rat model of early Parkinson\u2019s disease revealed by in vivo PET imaging. Sci Rep 15(1):15943. https:\/\/doi.org\/10.1038\/s41598-025-99580-x","journal-title":"Sci Rep"},{"issue":"8","key":"6021_CR55","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1002\/mds.28632","volume":"36","author":"V Kaasinen","year":"2021","unstructured":"Kaasinen V, Vahlberg T, Stoessl AJ, Strafella AP, Antonini A (2021) Dopamine receptors in Parkinson\u2019s disease: a meta-analysis of imaging studies. Mov Disord 36(8):1781\u20131791. https:\/\/doi.org\/10.1002\/mds.28632","journal-title":"Mov Disord"},{"key":"6021_CR56","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.nicl.2017.08.013","volume":"16","author":"M Politis","year":"2017","unstructured":"Politis M, Wilson H, Wu K, Brooks DJ, Piccini P (2017) Chronic exposure to dopamine agonists affects the integrity of striatal D(2) receptors in Parkinson\u2019s patients. Neuroimage Clin 16:455\u2013460. https:\/\/doi.org\/10.1016\/j.nicl.2017.08.013","journal-title":"Neuroimage Clin"},{"issue":"11","key":"6021_CR57","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1093\/brain\/awz298","volume":"142","author":"P Barbosa","year":"2019","unstructured":"Barbosa P, Hapuarachchi B, Djamshidian A, Strand K, Lees AJ, de Silva R, Holton JL, Warner TT (2019) Lower nucleus accumbens alpha-synuclein load and D3 receptor levels in Parkinson\u2019s disease with impulsive compulsive behaviours. Brain 142(11):3580\u20133591. https:\/\/doi.org\/10.1093\/brain\/awz298","journal-title":"Brain"},{"issue":"7","key":"6021_CR58","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1212\/wnl.54.7.1482","volume":"54","author":"V Kaasinen","year":"2000","unstructured":"Kaasinen V, Nagren K, Hietala J, Oikonen V, Vilkman H, Farde L, Halldin C, Rinne JO (2000) Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson\u2019s disease. Neurology 54(7):1482\u20131487. https:\/\/doi.org\/10.1212\/wnl.54.7.1482","journal-title":"Neurology"},{"key":"6021_CR59","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.nicl.2018.02.010","volume":"18","author":"AJ Stark","year":"2018","unstructured":"Stark AJ, Smith CT, Petersen KJ, Trujillo P, van Wouwe NC, Donahue MJ, Kessler RM, Deutch AY et al (2018) [(18)F]fallypride characterization of striatal and extrastriatal D(2\/3) receptors in Parkinson\u2019s disease. Neuroimage Clin 18:433\u2013442. https:\/\/doi.org\/10.1016\/j.nicl.2018.02.010","journal-title":"Neuroimage Clin"},{"key":"6021_CR60","doi-asserted-by":"publisher","unstructured":"Li M, Xu H, Chen G, Sun S, Wang Q, Liu B, Wu X, Zhou L et al (2019) Impaired D2 receptor-dependent dopaminergic transmission in prefrontal cortex of awake mouse model of Parkinson\u2019s disease. Brain 142(10):3099\u20133115. https:\/\/doi.org\/10.1093\/brain\/awz243","DOI":"10.1093\/brain\/awz243"},{"key":"6021_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2019.101906","volume":"23","author":"EA Pelzer","year":"2019","unstructured":"Pelzer EA, Melzer C, Schonberger A, Hess M, Timmermann L, Eggers C, Tittgemeyer M (2019) Axonal degeneration in Parkinson\u2019s disease - basal ganglia circuitry and D2 receptor availability. Neuroimage Clin 23:101906. https:\/\/doi.org\/10.1016\/j.nicl.2019.101906","journal-title":"Neuroimage Clin"},{"issue":"1","key":"6021_CR62","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ana.20296","volume":"57","author":"I Aubert","year":"2005","unstructured":"Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N, Bioulac BH, Gross CE et al (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57(1):17\u201326. https:\/\/doi.org\/10.1002\/ana.20296","journal-title":"Ann Neurol"},{"issue":"1","key":"6021_CR63","doi-asserted-by":"publisher","first-page":"14426","DOI":"10.1038\/s41598-020-71121-8","volume":"10","author":"J Jones-Tabah","year":"2020","unstructured":"Jones-Tabah J, Mohammad H, Hadj-Youssef S, Kim LEH, Martin RD, Benaliouad F, Tanny JC, Clarke PBS et al (2020) Dopamine D1 receptor signalling in dyskinetic Parkinsonian rats revealed by fiber photometry using FRET-based biosensors. Sci Rep 10(1):14426. https:\/\/doi.org\/10.1038\/s41598-020-71121-8","journal-title":"Sci Rep"},{"key":"6021_CR64","doi-asserted-by":"publisher","unstructured":"Payer DE, Guttman M, Kish SJ, Tong J, Adams JR, Rusjan P, Houle S, Furukawa Y et al (2016) D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia. Neurology 86(3):224\u2013230. https:\/\/doi.org\/10.1212\/WNL.0000000000002285","DOI":"10.1212\/WNL.0000000000002285"},{"key":"6021_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2020.147266","volume":"1754","author":"Y Wang","year":"2021","unstructured":"Wang Y, Yao L, Gao S, Zhang G, Zhang Q, Liu W, Zhou Y, Sun Y et al (2021) Inhibition of striatal dopamine D(5) receptor attenuates levodopa-induced dyskinesia in a rat model of Parkinson\u2019s disease. Brain Res 1754:147266. https:\/\/doi.org\/10.1016\/j.brainres.2020.147266","journal-title":"Brain Res"},{"issue":"24","key":"6021_CR66","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1523\/JNEUROSCI.23-24-08506.2003","volume":"23","author":"D Centonze","year":"2003","unstructured":"Centonze D, Grande C, Saulle E, Martin AB, Gubellini P, Pavon N, Pisani A, Bernardi G et al (2003) Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J Neurosci 23(24):8506\u20138512. https:\/\/doi.org\/10.1523\/JNEUROSCI.23-24-08506.2003","journal-title":"J Neurosci"},{"key":"6021_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2025.106968","volume":"212","author":"S Bompierre","year":"2025","unstructured":"Bompierre S, Yapo C, Blaise R, Vincent P, Castro LRV (2025) Activation of PDE2A moderates pathologically high cAMP\/PKA responses to dopamine in dyskinetic mice. Neurobiol Dis 212:106968. https:\/\/doi.org\/10.1016\/j.nbd.2025.106968","journal-title":"Neurobiol Dis"},{"key":"6021_CR68","doi-asserted-by":"publisher","unstructured":"Rodriguez Sarmiento RM, Berchtold S, Manevski N, Lindemann L, Dey F, Clairfeuille T, Amendola D, Vautrelle N et al (2025) Orally bioavailable dopamine D1\/D5 receptor-biased agonists to study the role of beta-arrestin in treatment-related dyskinesia in Parkinson\u2019s disease. J Med Chem 68(13):13532\u201313561. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00294","DOI":"10.1021\/acs.jmedchem.5c00294"},{"key":"6021_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107826","volume":"218","author":"AH Evans","year":"2025","unstructured":"Evans AH, Ciruela-Jardi M, Rea W, Keegan BM, Levinstein MR, Bonifazi A, Cao J, Jackson SN et al (2025) Locomotor activity depends on \u03b2-arrestin recruitment by the dopamine D1 receptor in the striatal D1-D3 receptor heteromer. Pharmacol Res 218:107826. https:\/\/doi.org\/10.1016\/j.phrs.2025.107826","journal-title":"Pharmacol Res"},{"key":"6021_CR70","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.neuint.2018.11.020","volume":"122","author":"A Mishra","year":"2019","unstructured":"Mishra A, Singh S, Tiwari V, Parul SS (2019) Dopamine D1 receptor activation improves adult hippocampal neurogenesis and exerts anxiolytic and antidepressant-like effect via activation of Wnt\/beta-catenin pathways in rat model of Parkinson\u2019s disease. Neurochem Int 122:170\u2013186. https:\/\/doi.org\/10.1016\/j.neuint.2018.11.020","journal-title":"Neurochem Int"},{"key":"6021_CR71","doi-asserted-by":"publisher","unstructured":"Pike AF, Longhena F, Faustini G, van Eik JM, Gombert I, Herrebout MAC, Fayed M, Sandre M et al (2022) Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson\u2019s disease. J Neuroinflammation 19(1):50. https:\/\/doi.org\/10.1186\/s12974-022-02410-4","DOI":"10.1186\/s12974-022-02410-4"},{"key":"6021_CR72","doi-asserted-by":"publisher","unstructured":"Zhang X, Zhou Z, Wang D, Li A, Yin Y, Gu X, Ding F, Zhen X et al (2009) Activation of phosphatidylinositol-linked D1-like receptor modulates FGF-2 expression in astrocytes via IP3-dependent Ca2+ signaling. J Neurosci 29(24):7766\u20137775. https:\/\/doi.org\/10.1523\/JNEUROSCI.0389-09.2009","DOI":"10.1523\/JNEUROSCI.0389-09.2009"},{"issue":"5","key":"6021_CR73","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13588","volume":"21","author":"L Ying","year":"2022","unstructured":"Ying L, Zhao J, Ye Y, Liu Y, Xiao B, Xue T, Zhu H, Wu Y et al (2022) Regulation of Cdc42 signaling by the dopamine D2 receptor in a mouse model of Parkinson\u2019s disease. Aging Cell 21(5):e13588. https:\/\/doi.org\/10.1111\/acel.13588","journal-title":"Aging Cell"},{"issue":"8","key":"6021_CR74","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nn.2592","volume":"13","author":"MJ Higley","year":"2010","unstructured":"Higley MJ, Sabatini BL (2010) Competitive regulation of synaptic Ca2+ influx by D2 dopamine and A2A adenosine receptors. Nat Neurosci 13(8):958\u2013966. https:\/\/doi.org\/10.1038\/nn.2592","journal-title":"Nat Neurosci"},{"issue":"2","key":"6021_CR75","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41419-017-0221-2","volume":"9","author":"A Tozzi","year":"2018","unstructured":"Tozzi A, Tantucci M, Marchi S, Mazzocchetti P, Morari M, Pinton P, Mancini A, Calabresi P (2018) Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson\u2019s disease. Cell Death Dis 9(2):204. https:\/\/doi.org\/10.1038\/s41419-017-0221-2","journal-title":"Cell Death Dis"},{"issue":"11","key":"6021_CR76","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1080\/15548627.2015.1100930","volume":"11","author":"JD Wang","year":"2015","unstructured":"Wang JD, Cao YL, Li Q, Yang YP, Jin M, Chen D, Wang F, Wang GH et al (2015) A pivotal role of FOS-mediated BECN1\/Beclin 1 upregulation in dopamine D2 and D3 receptor agonist-induced autophagy activation. Autophagy 11(11):2057\u20132073. https:\/\/doi.org\/10.1080\/15548627.2015.1100930","journal-title":"Autophagy"},{"issue":"1","key":"6021_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1302-6","volume":"15","author":"RH Du","year":"2018","unstructured":"Du RH, Zhou Y, Xia ML, Lu M, Ding JH, Hu G (2018) Alpha-synuclein disrupts the anti-inflammatory role of Drd2 via interfering beta-arrestin2-TAB1 interaction in astrocytes. J Neuroinflammation 15(1):258. https:\/\/doi.org\/10.1186\/s12974-018-1302-6","journal-title":"J Neuroinflammation"},{"key":"6021_CR78","doi-asserted-by":"publisher","unstructured":"Zhu J, Hu Z, Han X, Wang D, Jiang Q, Ding J, Xiao M, Wang C et al (2018) Dopamine D2 receptor restricts astrocytic NLRP3 inflammasome activation via enhancing the interaction of beta-arrestin2 and NLRP3. Cell Death Differ 25(11):2037\u20132049. https:\/\/doi.org\/10.1038\/s41418-018-0127-2","DOI":"10.1038\/s41418-018-0127-2"},{"key":"6021_CR79","doi-asserted-by":"publisher","unstructured":"Dong AQ, Yang YP, Jiang SM, Yao XY, Qi D, Mao CJ, Cheng XY, Wang F et al (2023) Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson\u2019s disease. Acta Pharmacol Sin 44(1):32\u201343. https:\/\/doi.org\/10.1038\/s41401-022-00951-1","DOI":"10.1038\/s41401-022-00951-1"},{"key":"6021_CR80","doi-asserted-by":"publisher","unstructured":"Elgueta D, Aymerich MS, Contreras F, Montoya A, Celorrio M, Rojo-Bustamante E, Riquelme E, Gonzalez H et al (2017) Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson\u2019s disease. Neuropharmacology 113(Pt A):110\u2013123. https:\/\/doi.org\/10.1016\/j.neuropharm.2016.09.028","DOI":"10.1016\/j.neuropharm.2016.09.028"},{"issue":"1","key":"6021_CR81","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12974-019-1652-8","volume":"16","author":"A Montoya","year":"2019","unstructured":"Montoya A, Elgueta D, Campos J, Chovar O, Falcon P, Matus S, Alfaro I, Bono MR et al (2019) Dopamine receptor D3 signalling in astrocytes promotes neuroinflammation. J Neuroinflammation 16(1):258. https:\/\/doi.org\/10.1186\/s12974-019-1652-8","journal-title":"J Neuroinflammation"},{"key":"6021_CR82","doi-asserted-by":"publisher","unstructured":"Elgueta D, Contreras F, Prado C, Montoya A, Ugalde V, Chovar O, Villagra R, Henriquez C et al (2019) Dopamine receptor D3 expression is altered in CD4(+) T-cells from Parkinson\u2019s disease patients and its pharmacologic inhibition attenuates the motor impairment in a mouse model. Front Immunol 10:981. https:\/\/doi.org\/10.3389\/fimmu.2019.00981","DOI":"10.3389\/fimmu.2019.00981"},{"key":"6021_CR83","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.bbi.2021.08.220","volume":"98","author":"Z Liu","year":"2021","unstructured":"Liu Z, Zhai XR, Du ZS, Xu FF, Huang Y, Wang XQ, Qiu YH, Peng YP (2021) Dopamine receptor D2 on CD4(+) T cells is protective against neuroinflammation and neurodegeneration in a mouse model of Parkinson\u2019s disease. Brain Behav Immun 98:110\u2013121. https:\/\/doi.org\/10.1016\/j.bbi.2021.08.220","journal-title":"Brain Behav Immun"},{"key":"6021_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114809","volume":"158","author":"Q Zhao","year":"2025","unstructured":"Zhao Q, Zhang X, Zhang J, Zhang Y, Jia L, Guo S, Zhang M, Wang H et al (2025) Reduction of D2 receptors on microglia leads to ZBP1-mediated PANoptosis of mPFC in Parkinson\u2019s disease depression mice. Int Immunopharmacol 158:114809. https:\/\/doi.org\/10.1016\/j.intimp.2025.114809","journal-title":"Int Immunopharmacol"},{"key":"6021_CR85","doi-asserted-by":"publisher","unstructured":"Sun X, Wang Y, Zhang Y, Han R, Wang M, Zhang J, Sun T, Liu Y et al (2025) Astrocyte FGF7\/FGFR2 autocrine signaling mediates neuroinflammation and promotes MPTP-induced degeneration of dopaminergic neurons. Acta Pharm Sin B 15(9):4730\u20134750. https:\/\/doi.org\/10.1016\/j.apsb.2025.07.012","DOI":"10.1016\/j.apsb.2025.07.012"},{"issue":"1","key":"6021_CR86","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/mds.23895","volume":"27","author":"B Ballanger","year":"2012","unstructured":"Ballanger B, Klinger H, Eche J, Lerond J, Vallet AE, Le Bars D, Tremblay L, Sgambato-Faure V et al (2012) Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson\u2019s disease. Mov Disord 27(1):84\u201389. https:\/\/doi.org\/10.1002\/mds.23895","journal-title":"Mov Disord"},{"key":"6021_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/biom15040592","author":"NL Gonzaga","year":"2025","unstructured":"Gonzaga NL, Karim F, Liang C, Mukherjee J (2025) [(18)F]Mefway: imaging serotonin 5HT(1A) receptors in human postmortem Alzheimer\u2019s and Parkinson\u2019s disease anterior cingulate. Potential applications to human positron emission tomography studies. Biomolecules. https:\/\/doi.org\/10.3390\/biom15040592","journal-title":"Biomolecules"},{"issue":"8","key":"6021_CR88","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1177\/0271678X20982389","volume":"41","author":"LM Jorgensen","year":"2021","unstructured":"Jorgensen LM, Henriksen T, Mardosiene S, Keller SH, Stenbaek DS, Hansen HD, Jespersen B, Thomsen C et al (2021) Parkinson patients have a presynaptic serotonergic deficit: a dynamic deep brain stimulation PET study. J Cereb Blood Flow Metab 41(8):1954\u20131963. https:\/\/doi.org\/10.1177\/0271678X20982389","journal-title":"J Cereb Blood Flow Metab"},{"key":"6021_CR89","doi-asserted-by":"publisher","unstructured":"Varrone A, Svenningsson P, Forsberg A, Varnas K, Tiger M, Nakao R, Halldin C, Nilsson LG et al (2014) Positron emission tomography imaging of 5-hydroxytryptamine1B receptors in Parkinson\u2019s disease. Neurobiol Aging 35(4):867\u2013875. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2013.08.025","DOI":"10.1016\/j.neurobiolaging.2013.08.025"},{"issue":"7","key":"6021_CR90","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.bcp.2013.08.005","volume":"86","author":"G Riahi","year":"2013","unstructured":"Riahi G, Morissette M, Samadi P, Parent M, Di Paolo T (2013) Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia. Biochem Pharmacol 86(7):970\u2013978. https:\/\/doi.org\/10.1016\/j.bcp.2013.08.005","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"6021_CR91","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3233\/JPD-130300","volume":"4","author":"M Melse","year":"2014","unstructured":"Melse M, Tan SK, Temel Y, van Kroonenburgh MJ, Leentjens AF (2014) Changes in 5-HT2A receptor expression in untreated, de novo patients with Parkinson\u2019s disease. J Parkinsons Dis 4(2):283\u2013287. https:\/\/doi.org\/10.3233\/JPD-130300","journal-title":"J Parkinsons Dis"},{"key":"6021_CR92","doi-asserted-by":"publisher","unstructured":"Cho SS, Strafella AP, Duff-Canning S, Zurowski M, Vijverman AC, Bruno V, Aquino CC, Criaud M et al (2017) The relationship between serotonin-2A receptor and cognitive functions in nondemented Parkinson\u2019s disease patients with visual hallucinations. Mov Disord Clin Pract 4(5):698\u2013709. https:\/\/doi.org\/10.1002\/mdc3.12466","DOI":"10.1002\/mdc3.12466"},{"issue":"2","key":"6021_CR93","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3233\/JPD-230331","volume":"14","author":"R Cirillo","year":"2024","unstructured":"Cirillo R, Duperrier S, Parekh P, Millot M, Li Q, Thiolat ML, Morelli M, Xie J et al (2024) Striatal serotonin 4 receptor is increased in experimental parkinsonism and dyskinesia. J Parkinsons Dis 14(2):261\u2013267. https:\/\/doi.org\/10.3233\/JPD-230331","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"6021_CR94","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1172\/JCI71640","volume":"124","author":"M Politis","year":"2014","unstructured":"Politis M, Wu K, Loane C, Brooks DJ, Kiferle L, Turkheimer FE, Bain P, Molloy S et al (2014) Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson\u2019s disease patients. J Clin Invest 124(3):1340\u20131349. https:\/\/doi.org\/10.1172\/JCI71640","journal-title":"J Clin Invest"},{"issue":"8","key":"6021_CR95","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/mds.20370","volume":"20","author":"W Bara-Jimenez","year":"2005","unstructured":"Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitrova T, Sherzai A, Mouradian MM, Chase TN (2005) Effects of serotonin 5-HT1A agonist in advanced Parkinson\u2019s disease. Mov Disord 20(8):932\u2013936. https:\/\/doi.org\/10.1002\/mds.20370","journal-title":"Mov Disord"},{"issue":"6","key":"6021_CR96","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s12264-007-0047-5","volume":"23","author":"J Cao","year":"2007","unstructured":"Cao J, Liu J, Zhang QJ, Wang T, Wang S, Han LN, Li Q (2007) The selective 5-HT1A receptor antagonist WAY-100635 inhibits neuronal activity of the ventromedial prefrontal cortex in a rodent model of Parkinson\u2019s disease. Neurosci Bull 23(6):315\u2013322. https:\/\/doi.org\/10.1007\/s12264-007-0047-5","journal-title":"Neurosci Bull"},{"key":"6021_CR97","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neuropharm.2015.01.012","volume":"93","author":"H Iderberg","year":"2015","unstructured":"Iderberg H, McCreary AC, Varney MA, Cenci MA, Newman-Tancredi A (2015) Activity of serotonin 5-HT(1A) receptor \u2018biased agonists\u2019 in rat models of Parkinson\u2019s disease and L-DOPA-induced dyskinesia. Neuropharmacology 93:52\u201367. https:\/\/doi.org\/10.1016\/j.neuropharm.2015.01.012","journal-title":"Neuropharmacology"},{"issue":"5","key":"6021_CR98","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s11064-018-2514-y","volume":"43","author":"A Newman-Tancredi","year":"2018","unstructured":"Newman-Tancredi A, Varney MA, McCreary AC (2018) Effects of the serotonin 5-HT(1A) receptor biased agonists, F13714 and F15599, on striatal neurotransmitter levels following L-DOPA administration in hemi-parkinsonian rats. Neurochem Res 43(5):1035\u20131046. https:\/\/doi.org\/10.1007\/s11064-018-2514-y","journal-title":"Neurochem Res"},{"key":"6021_CR99","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.parkreldis.2020.08.009","volume":"78","author":"R Depoortere","year":"2020","unstructured":"Depoortere R, Johnston TH, Fox SH, Brotchie JM, Newman-Tancredi A (2020) The selective 5-HT(1A) receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques. Parkinsonism Relat Disord 78:151\u2013157. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.08.009","journal-title":"Parkinsonism Relat Disord"},{"key":"6021_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.107997","volume":"167","author":"R Fisher","year":"2020","unstructured":"Fisher R, Hikima A, Morris R, Jackson MJ, Rose S, Varney MA, Depoortere R, Newman-Tancredi A (2020) The selective 5-HT(1A) receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets. Neuropharmacology 167:107997. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.107997","journal-title":"Neuropharmacology"},{"key":"6021_CR101","doi-asserted-by":"publisher","unstructured":"Svenningsson P, Odin P, Bergquist F, Wirdefeldt K, Nyholm D, Andreasson M, Markaki I, Johansson AC et al (2025) NLX-112 Randomized phase 2A trial: safety, tolerability, anti-dyskinetic, and anti-parkinsonian efficacy. Mov Disord 40(6):1134\u20131142. https:\/\/doi.org\/10.1002\/mds.30175","DOI":"10.1002\/mds.30175"},{"issue":"19","key":"6021_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26195790","volume":"26","author":"F Altwal","year":"2021","unstructured":"Altwal F, Padovan-Neto FE, Ritger A, Steiner H, West AR (2021) Role of 5-HT1A receptor in vilazodone-mediated suppression of L-DOPA-induced dyskinesia and increased responsiveness to cortical input in striatal medium spiny neurons in an animal model of Parkinson\u2019s disease. Molecules 26(19):5790. https:\/\/doi.org\/10.3390\/molecules26195790","journal-title":"Molecules"},{"key":"6021_CR103","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.brainres.2013.09.020","volume":"1537","author":"D Lindenbach","year":"2013","unstructured":"Lindenbach D, Dupre KB, Eskow Jaunarajs KL, Ostock CY, Goldenberg AA, Bishop C (2013) Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson\u2019s disease. Brain Res 1537:327\u2013339. https:\/\/doi.org\/10.1016\/j.brainres.2013.09.020","journal-title":"Brain Res"},{"issue":"2","key":"6021_CR104","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s12035-019-01739-x","volume":"57","author":"FE Padovan-Neto","year":"2020","unstructured":"Padovan-Neto FE, Patterson S, Nm FV, Altwal F, Beverley JA, West AR, Steiner H (2020) Selective regulation of 5-HT1B serotonin receptor expression in the striatum by dopamine depletion and repeated L-DOPA treatment: relationship to L-DOPA-induced dyskinesias. Mol Neurobiol 57(2):736\u2013751. https:\/\/doi.org\/10.1007\/s12035-019-01739-x","journal-title":"Mol Neurobiol"},{"issue":"Pt 7","key":"6021_CR105","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1093\/brain\/awm082","volume":"130","author":"M Carta","year":"2007","unstructured":"Carta M, Carlsson T, Kirik D, Bjorklund A (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130(Pt 7):1819\u20131833. https:\/\/doi.org\/10.1093\/brain\/awm082","journal-title":"Brain"},{"key":"6021_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2022.114209","volume":"358","author":"M Thomsen","year":"2022","unstructured":"Thomsen M, Stoica A, Christensen KV, Fryland T, Mikkelsen JD, Hansen JB (2022) Synergistic effect of serotonin 1A and serotonin 1B\/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats. Exp Neurol 358:114209. https:\/\/doi.org\/10.1016\/j.expneurol.2022.114209","journal-title":"Exp Neurol"},{"issue":"45","key":"6021_CR107","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adx4577","volume":"11","author":"M Molinari","year":"2025","unstructured":"Molinari M, Aaltonen A, Lieberman OJ, Sulzer D, Santini E, Borgkvist A (2025) Dopamine and serotonin cotransmission filters striatonigral synaptic activity via 5-HT1B receptor activation. Sci Adv 11(45):eadx4577. https:\/\/doi.org\/10.1126\/sciadv.adx4577","journal-title":"Sci Adv"},{"issue":"10","key":"6021_CR108","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.3390\/cells9102265","volume":"9","author":"F Altwal","year":"2020","unstructured":"Altwal F, Moon C, West AR, Steiner H (2020) The multimodal serotonergic agent vilazodone inhibits L-DOPA-induced gene regulation in striatal projection neurons and associated dyskinesia in an animal model of Parkinson\u2019s disease. Cells 9(10):2265. https:\/\/doi.org\/10.3390\/cells9102265","journal-title":"Cells"},{"key":"6021_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108693","volume":"196","author":"A Pinna","year":"2021","unstructured":"Pinna A, Costa G, Serra M, Contu L, Morelli M (2021) Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson\u2019s disease are counteracted by combined administration of a 5-HT(1A\/1B) receptor agonist and A(2A) receptor antagonist. Neuropharmacology 196:108693. https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108693","journal-title":"Neuropharmacology"},{"key":"6021_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2023.114488","volume":"449","author":"G Tang","year":"2023","unstructured":"Tang G, Guo Y, Zhang L, Wang T, Li R, Yang J, Wang Y, Liu J (2023) 5-HT(1B) receptors in the basolateral amygdaloid nucleus regulate anxiety-like behaviors through AC-PKA signal pathway in a rat model of Parkinson\u2019s disease. Behav Brain Res 449:114488. https:\/\/doi.org\/10.1016\/j.bbr.2023.114488","journal-title":"Behav Brain Res"},{"key":"6021_CR111","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.nbd.2013.08.003","volume":"59","author":"I Miyazaki","year":"2013","unstructured":"Miyazaki I, Asanuma M, Murakami S, Takeshima M, Torigoe N, Kitamura Y, Miyoshi K (2013) Targeting 5-HT(1A) receptors in astrocytes to protect dopaminergic neurons in Parkinsonian models. Neurobiol Dis 59:244\u2013256. https:\/\/doi.org\/10.1016\/j.nbd.2013.08.003","journal-title":"Neurobiol Dis"},{"key":"6021_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2019.104608","volume":"132","author":"N Isooka","year":"2020","unstructured":"Isooka N, Miyazaki I, Kikuoka R, Wada K, Nakayama E, Shin K, Yamamoto D, Kitamura Y et al (2020) Dopaminergic neuroprotective effects of rotigotine via 5-HT1A receptors: possibly involvement of metallothionein expression in astrocytes. Neurochem Int 132:104608. https:\/\/doi.org\/10.1016\/j.neuint.2019.104608","journal-title":"Neurochem Int"},{"key":"6021_CR113","doi-asserted-by":"publisher","unstructured":"Kikuoka R, Miyazaki I, Kubota N, Maeda M, Kagawa D, Moriyama M, Sato A, Murakami S et al (2020) Mirtazapine exerts astrocyte-mediated dopaminergic neuroprotection. Sci Rep 10(1):20698. https:\/\/doi.org\/10.1038\/s41598-020-77652-4","DOI":"10.1038\/s41598-020-77652-4"},{"issue":"6","key":"6021_CR114","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3390\/cells10061312","volume":"10","author":"S Thomas Broome","year":"2021","unstructured":"Thomas Broome S, Fisher T, Faiz A, Keay KA, Musumeci G, Al-Badri G, Castorina A (2021) Assessing the anti-inflammatory activity of the anxiolytic drug buspirone using CRISPR-Cas9 gene editing in LPS-stimulated BV-2 microglial cells. Cells 10(6):1312. https:\/\/doi.org\/10.3390\/cells10061312","journal-title":"Cells"},{"issue":"2","key":"6021_CR115","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/bph.14076","volume":"175","author":"NE Scholpa","year":"2018","unstructured":"Scholpa NE, Lynn MK, Corum D, Boger HA, Schnellmann RG (2018) 5-HT(1F) receptor-mediated mitochondrial biogenesis for the treatment of Parkinson\u2019s disease. Br J Pharmacol 175(2):348\u2013358. https:\/\/doi.org\/10.1111\/bph.14076","journal-title":"Br J Pharmacol"},{"issue":"4","key":"6021_CR116","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/npp.2009.176","volume":"35","author":"HY Meltzer","year":"2010","unstructured":"Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH (2010) Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson\u2019s disease psychosis. Neuropsychopharmacology 35(4):881\u2013892. https:\/\/doi.org\/10.1038\/npp.2009.176","journal-title":"Neuropsychopharmacology"},{"key":"6021_CR117","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fnsys.2011.00048","volume":"5","author":"TA Ansah","year":"2011","unstructured":"Ansah TA, Ferguson MC, Nayyar T (2011) The 5-HT(2A) receptor antagonist M100907 produces antiparkinsonian effects and decreases striatal glutamate. Front Syst Neurosci 5:48. https:\/\/doi.org\/10.3389\/fnsys.2011.00048","journal-title":"Front Syst Neurosci"},{"key":"6021_CR118","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neuropharm.2014.11.025","volume":"91","author":"LB Li","year":"2015","unstructured":"Li LB, Zhang L, Sun YN, Han LN, Wu ZH, Zhang QJ, Liu J (2015) Activation of serotonin2A receptors in the medial septum-diagonal band of Broca complex enhanced working memory in the hemiparkinsonian rats. Neuropharmacology 91:23\u201333. https:\/\/doi.org\/10.1016\/j.neuropharm.2014.11.025","journal-title":"Neuropharmacology"},{"issue":"6","key":"6021_CR119","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/1531-8257(200011)15:6<1064::aid-mds1002>3.0.co;2-c","volume":"15","author":"SH Fox","year":"2000","unstructured":"Fox SH, Brotchie JM (2000) 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson\u2019s disease. Mov Disord 15(6):1064\u20131069. https:\/\/doi.org\/10.1002\/1531-8257(200011)15:6%3c1064::aid-mds1002%3e3.0.co;2-c","journal-title":"Mov Disord"},{"key":"6021_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2024.106559","volume":"198","author":"D Ballardin","year":"2024","unstructured":"Ballardin D, Makrini-Maleville L, Seper A, Valjent E, Rebholz H (2024) 5-HT4R agonism reduces L-DOPA-induced dyskinesia via striatopallidal neurons in unilaterally 6-OHDA lesioned mice. Neurobiol Dis 198:106559. https:\/\/doi.org\/10.1016\/j.nbd.2024.106559","journal-title":"Neurobiol Dis"},{"issue":"21","key":"6021_CR121","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.3390\/ijms20215340","volume":"20","author":"T Ishii","year":"2019","unstructured":"Ishii T, Kinoshita KI, Muroi Y (2019) Serotonin 5-HT(4) receptor agonists improve facilitation of contextual fear extinction in an MPTP-induced mouse model of Parkinson\u2019s disease. Int J Mol Sci 20(21):5340. https:\/\/doi.org\/10.3390\/ijms20215340","journal-title":"Int J Mol Sci"},{"key":"6021_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2025.105996","volume":"188","author":"J Yang","year":"2025","unstructured":"Yang J, Chen L, Li X, Guo Y, Hu H, Li F, Wang T, Wang Y et al (2025) Activation or blockade of prelimbic 5-HT(4) receptors improves working memory in hemiparkinsonian rats. Neurochem Int 188:105996. https:\/\/doi.org\/10.1016\/j.neuint.2025.105996","journal-title":"Neurochem Int"},{"key":"6021_CR123","doi-asserted-by":"publisher","unstructured":"Cui C, Shi Y, Hong H, Zhou Y, Qiao C, Zhao L, Jia X, Zhao W et al (2023) 5-HT4 receptor is protective for MPTP-induced Parkinson\u2019s disease mice via altering gastrointestinal motility or gut microbiota. J Neuroimmune Pharmacol 18(4):610\u2013627. https:\/\/doi.org\/10.1007\/s11481-023-10085-8","DOI":"10.1007\/s11481-023-10085-8"},{"key":"6021_CR124","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.neuropharm.2018.05.016","volume":"137","author":"YN Sun","year":"2018","unstructured":"Sun YN, Yao L, Li LB, Wang Y, Du CX, Guo Y, Liu J (2018) Activation and blockade of basolateral amygdala 5-HT(6) receptor produce anxiolytic-like behaviors in an experimental model of Parkinson\u2019s disease. Neuropharmacology 137:275\u2013285. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.05.016","journal-title":"Neuropharmacology"},{"key":"6021_CR125","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.neuropharm.2015.03.031","volume":"95","author":"KC Liu","year":"2015","unstructured":"Liu KC, Li JY, Tan HH, Du CX, Xie W, Zhang YM, Ma WL, Zhang L (2015) Serotonin(6) receptors in the dorsal hippocampus regulate depressive-like behaviors in unilateral 6-hydroxydopamine-lesioned Parkinson\u2019s rats. Neuropharmacology 95:290\u2013298. https:\/\/doi.org\/10.1016\/j.neuropharm.2015.03.031","journal-title":"Neuropharmacology"},{"key":"6021_CR126","doi-asserted-by":"publisher","unstructured":"Zhang YM, Zhang L, Wang Y, Sun YN, Guo Y, Du CX, Zhang J, Yao L et al (2016) Activation and blockade of prelimbic 5-HT6 receptors produce different effects on depressive-like behaviors in unilateral 6-hydroxydopamine-induced Parkinson\u2019s rats. Neuropharmacology 110(Pt A):25\u201336. https:\/\/doi.org\/10.1016\/j.neuropharm.2016.07.014","DOI":"10.1016\/j.neuropharm.2016.07.014"},{"issue":"5","key":"6021_CR127","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.neuron.2016.04.017","volume":"90","author":"P Aldrin-Kirk","year":"2016","unstructured":"Aldrin-Kirk P, Heuer A, Wang G, Mattsson B, Lundblad M, Parmar M, Bjorklund T (2016) DREADD modulation of transplanted DA neurons reveals a novel parkinsonian dyskinesia mechanism mediated by the serotonin 5-HT6 receptor. Neuron 90(5):955\u2013968. https:\/\/doi.org\/10.1016\/j.neuron.2016.04.017","journal-title":"Neuron"},{"key":"6021_CR128","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.brainres.2016.05.016","volume":"1644","author":"LN Han","year":"2016","unstructured":"Han LN, Zhang L, Sun YN, Du CX, Zhang YM, Wang T, Zhang J, Liu J (2016) Serotonin7 receptors in the lateral habenular nucleus regulate depressive-like behaviors in the hemiparkinsonian rats. Brain Res 1644:79\u201387. https:\/\/doi.org\/10.1016\/j.brainres.2016.05.016","journal-title":"Brain Res"},{"key":"6021_CR129","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.neuroscience.2015.10.016","volume":"311","author":"QJ Zhang","year":"2015","unstructured":"Zhang QJ, Du CX, Tan HH, Zhang L, Li LB, Zhang J, Niu XL, Liu J (2015) Activation and blockade of serotonin7 receptors in the prelimbic cortex regulate depressive-like behaviors in a 6-hydroxydopamine-induced Parkinson\u2019s disease rat model. Neuroscience 311:45\u201355. https:\/\/doi.org\/10.1016\/j.neuroscience.2015.10.016","journal-title":"Neuroscience"},{"key":"6021_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2025.115239","volume":"389","author":"J Yang","year":"2025","unstructured":"Yang J, Guo Y, Zhang L, Gao S, Liu J (2025) Involvement of the basolateral amygdaloid nucleus anterior part 5-HT(7) receptors in the regulation of anxiety-like behaviors in hemiparkinsonian rats. Exp Neurol 389:115239. https:\/\/doi.org\/10.1016\/j.expneurol.2025.115239","journal-title":"Exp Neurol"},{"issue":"7","key":"6021_CR131","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.neuron.2021.01.028","volume":"109","author":"Y Cai","year":"2021","unstructured":"Cai Y, Nielsen BE, Boxer EE, Aoto J, Ford CP (2021) Loss of nigral excitation of cholinergic interneurons contributes to parkinsonian motor impairments. Neuron 109(7):1137-1149 e1135. https:\/\/doi.org\/10.1016\/j.neuron.2021.01.028","journal-title":"Neuron"},{"key":"6021_CR132","doi-asserted-by":"publisher","unstructured":"Yamasaki T, Fujinaga M, Kawamura K, Furutsuka K, Nengaki N, Shimoda Y, Shiomi S, Takei M et al (2016) Dynamic changes in striatal mGluR1 but not mGluR5 during pathological progression of Parkinson\u2019s disease in human alpha-synuclein A53T transgenic rats: a multi-PET imaging study. J Neurosci 36(2):375\u2013384. https:\/\/doi.org\/10.1523\/JNEUROSCI.2289-15.2016","DOI":"10.1523\/JNEUROSCI.2289-15.2016"},{"issue":"1","key":"6021_CR133","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.neuroimage.2008.04.170","volume":"42","author":"R Sanchez-Pernaute","year":"2008","unstructured":"Sanchez-Pernaute R, Wang JQ, Kuruppu D, Cao L, Tueckmantel W, Kozikowski A, Isacson O, Brownell AL (2008) Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates. Neuroimage 42(1):248\u2013251. https:\/\/doi.org\/10.1016\/j.neuroimage.2008.04.170","journal-title":"Neuroimage"},{"issue":"9","key":"6021_CR134","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/sj.jcbfm.9600461","volume":"27","author":"A Zhu","year":"2007","unstructured":"Zhu A, Wang X, Yu M, Wang JQ, Brownell AL (2007) Evaluation of four pyridine analogs to characterize 6-OHDA-induced modulation of mGluR5 function in rat brain using microPET studies. J Cereb Blood Flow Metab 27(9):1623\u20131631. https:\/\/doi.org\/10.1038\/sj.jcbfm.9600461","journal-title":"J Cereb Blood Flow Metab"},{"key":"6021_CR135","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.neurobiolaging.2017.09.006","volume":"61","author":"M Crabbe","year":"2018","unstructured":"Crabbe M, Van der Perren A, Weerasekera A, Himmelreich U, Baekelandt V, Van Laere K, Casteels C (2018) Altered mGluR5 binding potential and glutamine concentration in the 6-OHDA rat model of acute Parkinson\u2019s disease and levodopa-induced dyskinesia. Neurobiol Aging 61:82\u201392. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.09.006","journal-title":"Neurobiol Aging"},{"key":"6021_CR136","doi-asserted-by":"publisher","unstructured":"Bezard E, Pioli EY, Li Q, Girard F, Mutel V, Keywood C, Tison F, Rascol O et al (2014) The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. Mov Disord 29(8):1074\u20131079. https:\/\/doi.org\/10.1002\/mds.25920","DOI":"10.1002\/mds.25920"},{"issue":"3","key":"6021_CR137","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.brainresbull.2005.12.009","volume":"69","author":"A Dekundy","year":"2006","unstructured":"Dekundy A, Pietraszek M, Schaefer D, Cenci MA, Danysz W (2006) Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson\u2019s disease. Brain Res Bull 69(3):318\u2013326. https:\/\/doi.org\/10.1016\/j.brainresbull.2005.12.009","journal-title":"Brain Res Bull"},{"key":"6021_CR138","doi-asserted-by":"publisher","unstructured":"Gregoire L, Morin N, Ouattara B, Gasparini F, Bilbe G, Johns D, Vranesic I, Sahasranaman S, et al. (2011) The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist. L-Dopa-treated parkinsonian monkeys. Parkinsonism Relat Disord 17(4):270\u2013276. https:\/\/doi.org\/10.1016\/j.parkreldis.2011.01.008","DOI":"10.1016\/j.parkreldis.2011.01.008"},{"issue":"7","key":"6021_CR139","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.neuropharm.2009.12.024","volume":"58","author":"N Morin","year":"2010","unstructured":"Morin N, Gregoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T (2010) Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 58(7):981\u2013986. https:\/\/doi.org\/10.1016\/j.neuropharm.2009.12.024","journal-title":"Neuropharmacology"},{"key":"6021_CR140","doi-asserted-by":"publisher","unstructured":"Rylander D, Iderberg H, Li Q, Dekundy A, Zhang J, Li H, Baishen R, Danysz W et al (2010) A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis 39(3):352\u2013361. https:\/\/doi.org\/10.1016\/j.nbd.2010.05.001","DOI":"10.1016\/j.nbd.2010.05.001"},{"key":"6021_CR141","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.neuropharm.2012.07.036","volume":"66","author":"N Morin","year":"2013","unstructured":"Morin N, Gregoire L, Morissette M, Desrayaud S, Gomez-Mancilla B, Gasparini F, Di Paolo T (2013) MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates. Neuropharmacology 66:355\u2013364. https:\/\/doi.org\/10.1016\/j.neuropharm.2012.07.036","journal-title":"Neuropharmacology"},{"key":"6021_CR142","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.neuropharm.2013.05.028","volume":"73","author":"N Morin","year":"2013","unstructured":"Morin N, Morissette M, Gregoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T (2013) Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys. Neuropharmacology 73:216\u2013231. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.05.028","journal-title":"Neuropharmacology"},{"key":"6021_CR143","doi-asserted-by":"publisher","unstructured":"Jenkins BG, Zhu A, Poutiainen P, Choi JK, Kil KE, Zhang Z, Kuruppu D, Aytan N et al (2016) Functional modulation of G-protein coupled receptors during Parkinson disease-like neurodegeneration. Neuropharmacology 108:462\u2013473. https:\/\/doi.org\/10.1016\/j.neuropharm.2015.11.010","DOI":"10.1016\/j.neuropharm.2015.11.010"},{"key":"6021_CR144","doi-asserted-by":"publisher","unstructured":"Sebastianutto I, Goyet E, Andreoli L, Font-Ingles J, Moreno-Delgado D, Bouquier N, Jahannault-Talignani C, Moutin E et al (2020) D1-mGlu5 heteromers mediate noncanonical dopamine signaling in Parkinson\u2019s disease. J Clin Invest 130(3):1168\u20131184. https:\/\/doi.org\/10.1172\/JCI126361","DOI":"10.1172\/JCI126361"},{"issue":"Pt 7","key":"6021_CR145","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1093\/brain\/awr137","volume":"134","author":"GJ Masilamoni","year":"2011","unstructured":"Masilamoni GJ, Bogenpohl JW, Alagille D, Delevich K, Tamagnan G, Votaw JR, Wichmann T, Smith Y (2011) Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain 134(Pt 7):2057\u20132073. https:\/\/doi.org\/10.1093\/brain\/awr137","journal-title":"Brain"},{"issue":"3","key":"6021_CR146","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.neulet.2010.09.043","volume":"486","author":"YD Black","year":"2010","unstructured":"Black YD, Xiao D, Pellegrino D, Kachroo A, Brownell AL, Schwarzschild MA (2010) Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson\u2019s disease. Neurosci Lett 486(3):161\u2013165. https:\/\/doi.org\/10.1016\/j.neulet.2010.09.043","journal-title":"Neurosci Lett"},{"issue":"1","key":"6021_CR147","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13041-023-01074-2","volume":"17","author":"V Xing","year":"2024","unstructured":"Xing V, Biggar K, Ferguson SSG, Hayley S (2024) In vitro modulation of mTOR and mGlur5 influence alpha-synuclein accumulation. Mol Brain 17(1):9. https:\/\/doi.org\/10.1186\/s13041-023-01074-2","journal-title":"Mol Brain"},{"key":"6021_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2020.103572","volume":"110","author":"JN Zhang","year":"2021","unstructured":"Zhang JN, Huang YL, Yang HM, Wang Y, Gu L, Zhang H (2021) Blockade of metabotropic glutamate receptor 5 attenuates axonal degeneration in 6-hydroxydopamine-induced model of Parkinson\u2019s disease. Mol Cell Neurosci 110:103572. https:\/\/doi.org\/10.1016\/j.mcn.2020.103572","journal-title":"Mol Cell Neurosci"},{"issue":"1","key":"6021_CR149","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12974-021-02079-1","volume":"18","author":"YN Zhang","year":"2021","unstructured":"Zhang YN, Fan JK, Gu L, Yang HM, Zhan SQ, Zhang H (2021) Metabotropic glutamate receptor 5 inhibits alpha-synuclein-induced microglia inflammation to protect from neurotoxicity in Parkinson\u2019s disease. J Neuroinflammation 18(1):23. https:\/\/doi.org\/10.1186\/s12974-021-02079-1","journal-title":"J Neuroinflammation"},{"issue":"3","key":"6021_CR150","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s13311-019-00730-7","volume":"16","author":"WY Luo","year":"2019","unstructured":"Luo WY, Xing SQ, Zhu P, Zhang CG, Yang HM, Van Halm-Lutterodt N, Gu L, Zhang H (2019) PDZ scaffold protein CAL couples with metabotropic glutamate receptor 5 to protect against cell apoptosis and is a potential target in the treatment of Parkinson\u2019s disease. Neurotherapeutics 16(3):761\u2013783. https:\/\/doi.org\/10.1007\/s13311-019-00730-7","journal-title":"Neurotherapeutics"},{"key":"6021_CR151","doi-asserted-by":"publisher","unstructured":"Xia N, Zhang Q, Wang ST, Gu L, Yang HM, Liu L, Bakshi R, Yang H et al (2015) Blockade of metabotropic glutamate receptor 5 protects against DNA damage in a rotenone-induced Parkinson\u2019s disease model. Free Radic Biol Med 89:567\u2013580. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2015.09.017","DOI":"10.1016\/j.freeradbiomed.2015.09.017"},{"key":"6021_CR152","doi-asserted-by":"publisher","unstructured":"Farmer K, Abd-Elrahman KS, Derksen A, Rowe EM, Thompson AM, Rudyk CA, Prowse NA, Dwyer Z et al (2020) mGluR5 allosteric modulation promotes neurorecovery in a 6-OHDA-toxicant model of Parkinson\u2019s disease. Mol Neurobiol 57(3):1418\u20131431. https:\/\/doi.org\/10.1007\/s12035-019-01818-z","DOI":"10.1007\/s12035-019-01818-z"},{"issue":"3","key":"6021_CR153","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/npp.2008.129","volume":"34","author":"E De Leonibus","year":"2009","unstructured":"De Leonibus E, Manago F, Giordani F, Petrosino F, Lopez S, Oliverio A, Amalric M, Mele A (2009) Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson\u2019s disease. Neuropsychopharmacology 34(3):729\u2013738. https:\/\/doi.org\/10.1038\/npp.2008.129","journal-title":"Neuropsychopharmacology"},{"key":"6021_CR154","doi-asserted-by":"publisher","unstructured":"Epping-Jordan MP, Girard F, Bessis AS, Mutel V, Bolea C, Derouet F, Bessif A, Mingard B et al (2023) Effect of the metabotropic glutamate receptor type 5 negative allosteric modulator dipraglurant on motor and non-motor symptoms of Parkinson\u2019s disease. Cells 12(7):1004. https:\/\/doi.org\/10.3390\/cells12071004","DOI":"10.3390\/cells12071004"},{"issue":"2","key":"6021_CR155","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.expneurol.2008.11.001","volume":"215","author":"G Martella","year":"2009","unstructured":"Martella G, Platania P, Vita D, Sciamanna G, Cuomo D, Tassone A, Tscherter A, Kitada T et al (2009) Enhanced sensitivity to group II mGlu receptor activation at corticostriatal synapses in mice lacking the familial parkinsonism-linked genes PINK1 or Parkin. Exp Neurol 215(2):388\u2013396. https:\/\/doi.org\/10.1016\/j.expneurol.2008.11.001","journal-title":"Exp Neurol"},{"issue":"Pt 12","key":"6021_CR156","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1093\/brain\/awf269","volume":"125","author":"B Picconi","year":"2002","unstructured":"Picconi B, Pisani A, Centonze D, Battaglia G, Storto M, Nicoletti F, Bernardi G, Calabresi P (2002) Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. Brain 125(Pt 12):2635\u20132645. https:\/\/doi.org\/10.1093\/brain\/awf269","journal-title":"Brain"},{"key":"6021_CR157","doi-asserted-by":"publisher","unstructured":"Tan Y, Xu Y, Cheng C, Zheng C, Zeng W, Wang J, Zhang X, Yang X et al (2020) LY354740 reduces extracellular glutamate concentration, inhibits phosphorylation of Fyn\/NMDARs, and expression of PLK2\/pS129 alpha-synuclein in mice treated with acute or sub-acute MPTP. Front Pharmacol 11:183. https:\/\/doi.org\/10.3389\/fphar.2020.00183","DOI":"10.3389\/fphar.2020.00183"},{"key":"6021_CR158","doi-asserted-by":"publisher","unstructured":"Di Menna L, Alborghetti M, De Bartolo MI, Borro M, Gentile G, Zinni M, Bologna M, Cutrona C et al (2025) Preclinical and clinical study on type 3 metabotropic glutamate receptors in Parkinson\u2019s disease. NPJ Parkinsons Dis 11(1):9. https:\/\/doi.org\/10.1038\/s41531-024-00860-6","DOI":"10.1038\/s41531-024-00860-6"},{"key":"6021_CR159","doi-asserted-by":"publisher","unstructured":"Frouni I, Hamadjida A, Kwan C, Bedard D, Nafade V, Gaudette F, Nuara SG, Gourdon JC et al (2019) Activation of mGlu(2\/3) receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism. Neuropharmacology 158:107725. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107725","DOI":"10.1016\/j.neuropharm.2019.107725"},{"key":"6021_CR160","doi-asserted-by":"publisher","unstructured":"Sid-Otmane L, Hamadjida A, Nuara SG, Bedard D, Gaudette F, Gourdon JC, Michaud V, Beaudry F et al (2020) Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset. Eur J Pharmacol 873:172957. https:\/\/doi.org\/10.1016\/j.ejphar.2020.172957","DOI":"10.1016\/j.ejphar.2020.172957"},{"key":"6021_CR161","doi-asserted-by":"publisher","unstructured":"Zheng C, Xu Y, Chen G, Tan Y, Zeng W, Wang J, Cheng C, Yang X et al (2020) Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: An electrophysiological perspective. Neurobiol Dis 139:104807. https:\/\/doi.org\/10.1016\/j.nbd.2020.104807","DOI":"10.1016\/j.nbd.2020.104807"},{"key":"6021_CR162","doi-asserted-by":"publisher","unstructured":"Kwan C, Frouni I, Nuara SG, Belliveau S, Kang W, Hamadjida A, Bedard D, Beaudry F et al (2021) Combined 5-HT(2A) and mGlu(2) modulation for the treatment of dyskinesia and psychosis in Parkinson\u2019s disease. Neuropharmacology 186:108465. https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108465","DOI":"10.1016\/j.neuropharm.2021.108465"},{"key":"6021_CR163","doi-asserted-by":"publisher","unstructured":"Samadi P, Gregoire L, Morissette M, Calon F, Hadj Tahar A, Belanger N, Dridi M, Bedard PJ et al (2008) Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias. Neuropharmacology 54(2):258\u2013268. https:\/\/doi.org\/10.1016\/j.neuropharm.2007.08.009","DOI":"10.1016\/j.neuropharm.2007.08.009"},{"issue":"9","key":"6021_CR164","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1523\/JNEUROSCI.20-09-03085.2000","volume":"20","author":"SR Bradley","year":"2000","unstructured":"Bradley SR, Marino MJ, Wittmann M, Rouse ST, Awad H, Levey AI, Conn PJ (2000) Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia nigra pars reticulata. J Neurosci 20(9):3085\u20133094. https:\/\/doi.org\/10.1523\/JNEUROSCI.20-09-03085.2000","journal-title":"J Neurosci"},{"issue":"6","key":"6021_CR165","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/jnr.20694","volume":"82","author":"L Wang","year":"2005","unstructured":"Wang L, Kitai ST, Xiang Z (2005) Modulation of excitatory synaptic transmission by endogenous glutamate acting on presynaptic group II mGluRs in rat substantia nigra compacta. J Neurosci Res 82(6):778\u2013787. https:\/\/doi.org\/10.1002\/jnr.20694","journal-title":"J Neurosci Res"},{"issue":"1","key":"6021_CR166","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/cns.12587","volume":"23","author":"YJ Jia","year":"2017","unstructured":"Jia YJ, Deng JH, Zhang WZ, Sun ZL, Yang J, Yu Y, Gong XL, Jia J et al (2017) The role of group II metabotropic glutamate receptors in the striatum in electroacupuncture treatment of parkinsonian rats. CNS Neurosci Ther 23(1):23\u201332. https:\/\/doi.org\/10.1111\/cns.12587","journal-title":"CNS Neurosci Ther"},{"issue":"7","key":"6021_CR167","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1111\/j.1476-5381.2010.00820.x","volume":"160","author":"PJ Austin","year":"2010","unstructured":"Austin PJ, Betts MJ, Broadstock M, O\u2019Neill MJ, Mitchell SN, Duty S (2010) Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson\u2019s disease. Br J Pharmacol 160(7):1741\u20131753. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00820.x","journal-title":"Br J Pharmacol"},{"issue":"2","key":"6021_CR168","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1124\/jpet.111.187443","volume":"340","author":"CK Jones","year":"2012","unstructured":"Jones CK, Bubser M, Thompson AD, Dickerson JW, Turle-Lorenzo N, Amalric M, Blobaum AL, Bridges TM et al (2012) The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson\u2019s disease. J Pharmacol Exp Ther 340(2):404\u2013421. https:\/\/doi.org\/10.1124\/jpet.111.187443","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"6021_CR169","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1124\/jpet.112.196063","volume":"343","author":"E Le Poul","year":"2012","unstructured":"Le Poul E, Bolea C, Girard F, Poli S, Charvin D, Campo B, Bortoli J, Bessif A et al (2012) A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson\u2019s disease. J Pharmacol Exp Ther 343(1):167\u2013177. https:\/\/doi.org\/10.1124\/jpet.112.196063","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"6021_CR170","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.nbd.2011.12.045","volume":"46","author":"S Lopez","year":"2012","unstructured":"Lopez S, Jouve L, Turle-Lorenzo N, Kerkerian-Legoff L, Salin P, Amalric M (2012) Antiparkinsonian action of a selective group III mGlu receptor agonist is associated with reversal of subthalamonigral overactivity. Neurobiol Dis 46(1):69\u201377. https:\/\/doi.org\/10.1016\/j.nbd.2011.12.045","journal-title":"Neurobiol Dis"},{"key":"6021_CR171","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.neuropharm.2012.03.022","volume":"66","author":"KE Bennouar","year":"2013","unstructured":"Bennouar KE, Uberti MA, Melon C, Bacolod MD, Jimenez HN, Cajina M, Kerkerian-Le Goff L, Doller D et al (2013) Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson\u2019s disease treatment and dyskinesia. Neuropharmacology 66:158\u2013169. https:\/\/doi.org\/10.1016\/j.neuropharm.2012.03.022","journal-title":"Neuropharmacology"},{"issue":"4","key":"6021_CR172","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3233\/JPD-2011-11066","volume":"1","author":"S Lopez","year":"2011","unstructured":"Lopez S, Bonito-Oliva A, Pallottino S, Acher F, Fisone G (2011) Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson\u2019s disease. J Parkinsons Dis 1(4):339\u2013346. https:\/\/doi.org\/10.3233\/JPD-2011-11066","journal-title":"J Parkinsons Dis"},{"issue":"10","key":"6021_CR173","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1002\/mds.27462","volume":"33","author":"D Charvin","year":"2018","unstructured":"Charvin D, Di Paolo T, Bezard E, Gregoire L, Takano A, Duvey G, Pioli E, Halldin C et al (2018) An mGlu4-positive allosteric modulator alleviates parkinsonism in primates. Mov Disord 33(10):1619\u20131631. https:\/\/doi.org\/10.1002\/mds.27462","journal-title":"Mov Disord"},{"issue":"2","key":"6021_CR174","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3233\/JPD-230296","volume":"14","author":"CJ Finlay","year":"2024","unstructured":"Finlay CJ, Jackson MJ, Fisher R, Bundgaard C, Rose S, Duty S (2024) Metabotropic glutamate receptor 4 (mGlu4) positive allosteric modulators lack efficacy in rat and marmoset models of L-DOPA-induced dyskinesia. J Parkinsons Dis 14(2):245\u2013259. https:\/\/doi.org\/10.3233\/JPD-230296","journal-title":"J Parkinsons Dis"},{"key":"6021_CR175","doi-asserted-by":"publisher","unstructured":"Iderberg H, Maslava N, Thompson AD, Bubser M, Niswender CM, Hopkins CR, Lindsley CW, Conn PJ et al (2015) Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson\u2019s disease and L-DOPA-induced dyskinesia: comparison between a positive allosteric modulator and an orthosteric agonist. Neuropharmacology 95:121\u2013129. https:\/\/doi.org\/10.1016\/j.neuropharm.2015.02.023","DOI":"10.1016\/j.neuropharm.2015.02.023"},{"issue":"2","key":"6021_CR176","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11481-016-9655-z","volume":"11","author":"R Ponnazhagan","year":"2016","unstructured":"Ponnazhagan R, Harms AS, Thome AD, Jurkuvenaite A, Gogliotti R, Niswender CM, Conn PJ, Standaert DG (2016) The metabotropic glutamate receptor 4 positive allosteric modulator ADX88178 inhibits inflammatory responses in primary microglia. J Neuroimmune Pharmacol 11(2):231\u2013237. https:\/\/doi.org\/10.1007\/s11481-016-9655-z","journal-title":"J Neuroimmune Pharmacol"},{"issue":"1","key":"6021_CR177","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41467-025-67731-3","volume":"17","author":"A Perez-Canamas","year":"2025","unstructured":"Perez-Canamas A, Chen M, Almandoz-Gil L, Khan N, Tang SJ, Ho A, Gunther EC, Strittmatter SM (2025) mGluR4-NPDC1 complex mediates alpha-synuclein fibril-induced neurodegeneration. Nat Commun 17(1):994. https:\/\/doi.org\/10.1038\/s41467-025-67731-3","journal-title":"Nat Commun"},{"issue":"4b","key":"6021_CR178","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1111\/j.1476-5381.2011.01515.x","volume":"165","author":"M Broadstock","year":"2012","unstructured":"Broadstock M, Austin PJ, Betts MJ, Duty S (2012) Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata. Br J Pharmacol 165(4b):1034\u20131045. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01515.x","journal-title":"Br J Pharmacol"},{"key":"6021_CR179","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.neuropharm.2012.03.029","volume":"66","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Jones CK, Tantawy MN, Bubser M, Marvanova M, Ansari MS, Baldwin RM, Conn PJ et al (2013) The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson\u2019s disease. Neuropharmacology 66:187\u2013195. https:\/\/doi.org\/10.1016\/j.neuropharm.2012.03.029","journal-title":"Neuropharmacology"},{"key":"6021_CR180","doi-asserted-by":"publisher","first-page":"175909141881102","DOI":"10.1177\/1759091418811021","volume":"10","author":"Y Huang","year":"2018","unstructured":"Huang Y, Shu H, Li L, Zhen T, Zhao J, Zhou X, Luo W (2018) L-DOPA-induced motor impairment and overexpression of corticostriatal synaptic components are improved by the mGluR5 antagonist MPEP in 6-OHDA-lesioned rats. ASN Neuro 10:1759091418811021. https:\/\/doi.org\/10.1177\/1759091418811021","journal-title":"ASN Neuro"},{"key":"6021_CR181","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.bbi.2018.04.006","volume":"71","author":"YY Huang","year":"2018","unstructured":"Huang YY, Zhang Q, Zhang JN, Zhang YN, Gu L, Yang HM, Xia N, Wang XM et al (2018) Triptolide up-regulates metabotropic glutamate receptor 5 to inhibit microglia activation in the lipopolysaccharide-induced model of Parkinson\u2019s disease. Brain Behav Immun 71:93\u2013107. https:\/\/doi.org\/10.1016\/j.bbi.2018.04.006","journal-title":"Brain Behav Immun"},{"issue":"5","key":"6021_CR182","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.neuron.2015.08.022","volume":"87","author":"A Borgkvist","year":"2015","unstructured":"Borgkvist A, Avegno EM, Wong MY, Kheirbek MA, Sonders MS, Hen R, Sulzer D (2015) Loss of striatonigral GABAergic presynaptic inhibition enables motor sensitization in parkinsonian mice. Neuron 87(5):976\u2013988. https:\/\/doi.org\/10.1016\/j.neuron.2015.08.022","journal-title":"Neuron"},{"issue":"1","key":"6021_CR183","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58007-x","volume":"16","author":"J Dong","year":"2025","unstructured":"Dong J, Wang L, Sullivan BT, Sun L, Martinez Smith VM, Chang L, Ding J, Le W et al (2025) Molecularly distinct striatonigral neuron subtypes differentially regulate locomotion. Nat Commun 16(1):2710. https:\/\/doi.org\/10.1038\/s41467-025-58007-x","journal-title":"Nat Commun"},{"issue":"Pt 3","key":"6021_CR184","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/brain\/awv403","volume":"139","author":"E Emmanouilidou","year":"2016","unstructured":"Emmanouilidou E, Minakaki G, Keramioti MV, Xylaki M, Balafas E, Chrysanthou-Piterou M, Kloukina I, Vekrellis K (2016) GABA transmission via ATP-dependent K+ channels regulates alpha-synuclein secretion in mouse striatum. Brain 139(Pt 3):871\u2013890. https:\/\/doi.org\/10.1093\/brain\/awv403","journal-title":"Brain"},{"issue":"2","key":"6021_CR185","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.neulet.2012.03.034","volume":"516","author":"R Hillman","year":"2012","unstructured":"Hillman R, Sinani J, Pendleton R (2012) The role of the GABA(B) receptor and calcium channels in a Drosophila model of Parkinson\u2019s disease. Neurosci Lett 516(2):167\u2013170. https:\/\/doi.org\/10.1016\/j.neulet.2012.03.034","journal-title":"Neurosci Lett"},{"issue":"2","key":"6021_CR186","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.etp.2014.12.001","volume":"67","author":"RK Tyagi","year":"2015","unstructured":"Tyagi RK, Bisht R, Pant J, Kumar P, Majeed AB, Prakash A (2015) Possible role of GABA-B receptor modulation in MPTP induced Parkinson\u2019s disease in rats. Exp Toxicol Pathol 67(2):211\u2013217. https:\/\/doi.org\/10.1016\/j.etp.2014.12.001","journal-title":"Exp Toxicol Pathol"},{"issue":"1\u20132","key":"6021_CR187","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.neulet.2006.07.004","volume":"406","author":"SJ Enna","year":"2006","unstructured":"Enna SJ, Reisman SA, Stanford JA (2006) CGP 56999A, a GABA(B) receptor antagonist, enhances expression of brain-derived neurotrophic factor and attenuates dopamine depletion in the rat corpus striatum following a 6-hydroxydopamine lesion of the nigrostriatal pathway. Neurosci Lett 406(1\u20132):102\u2013106. https:\/\/doi.org\/10.1016\/j.neulet.2006.07.004","journal-title":"Neurosci Lett"},{"key":"6021_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.110033","volume":"257","author":"R Li","year":"2024","unstructured":"Li R, Yang Y, Wang L, Tang G, Yang J, Gao S, Liu J (2024) Blockade of pre- and post-synaptic GABA(B) receptors in the anteroventral bed nucleus of stria terminalis produces anxiolytic-like and anxiety-like effects in parkinsonian rats respectively. Neuropharmacology 257:110033. https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110033","journal-title":"Neuropharmacology"},{"key":"6021_CR189","doi-asserted-by":"publisher","unstructured":"Wang Y, Xu H, Chen S, Chen J, Zheng Q, Ma Y, Zhao X, Shi Y et al (2024) Oxytocin protects nigrostriatal dopamine signal via activating GABAergic circuit in the MPTP-induced Parkinson\u2019s disease model. Adv Sci (Weinh) 11(36):e2310244. https:\/\/doi.org\/10.1002\/advs.202310244","DOI":"10.1002\/advs.202310244"},{"issue":"8","key":"6021_CR190","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1002\/mds.29117","volume":"37","author":"RM Ajalin","year":"2022","unstructured":"Ajalin RM, Al-Abdulrasul H, Tuisku JM, Hirvonen JES, Vahlberg T, Lahdenpohja S, Rinne JO, Bruck AE (2022) Cannabinoid receptor type 1 in Parkinson\u2019s disease: a positron emission tomography study with [(18) F]FMPEP-d(2). Mov Disord 37(8):1673\u20131682. https:\/\/doi.org\/10.1002\/mds.29117","journal-title":"Mov Disord"},{"issue":"2","key":"6021_CR191","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1006\/exnr.2001.7649","volume":"169","author":"MA Silverdale","year":"2001","unstructured":"Silverdale MA, McGuire S, McInnes A, Crossman AR, Brotchie JM (2001) Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson\u2019s disease. Exp Neurol 169(2):400\u2013406. https:\/\/doi.org\/10.1006\/exnr.2001.7649","journal-title":"Exp Neurol"},{"key":"6021_CR192","doi-asserted-by":"publisher","unstructured":"Ceccarini J, Casteels C, Ahmad R, Crabbe M, Van de Vliet L, Vanhaute H, Vandenbulcke M, Vandenberghe W et al (2019) Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson\u2019s disease. Eur J Nucl Med Mol Imaging 46(11):2348\u20132357. https:\/\/doi.org\/10.1007\/s00259-019-04445-x","DOI":"10.1007\/s00259-019-04445-x"},{"issue":"1","key":"6021_CR193","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/mds.30042","volume":"40","author":"R Ajalin","year":"2025","unstructured":"Ajalin R, Al-Abdulrasul H, Tuisku JM, Hirvonen J, Lahdenpohja S, Rinne JO, Bruck A (2025) Impaired gait, postural instability, and rigidity in relation to CB1 receptor availability in Parkinson\u2019s disease. Mov Disord 40(1):163\u2013167. https:\/\/doi.org\/10.1002\/mds.30042","journal-title":"Mov Disord"},{"key":"6021_CR194","doi-asserted-by":"publisher","unstructured":"Chung YC, Bok E, Huh SH, Park JY, Yoon SH, Kim SR, Kim YS, Maeng S et al (2011) Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J Immunol 187(12):6508\u20136517. https:\/\/doi.org\/10.4049\/jimmunol.1102435","DOI":"10.4049\/jimmunol.1102435"},{"issue":"9","key":"6021_CR195","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1096\/fj.04-3010fje","volume":"19","author":"M van der Stelt","year":"2005","unstructured":"van der Stelt M, Fox SH, Hill M, Crossman AR, Petrosino S, Di Marzo V, Brotchie JM (2005) A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson\u2019s disease. FASEB J 19(9):1140\u20131142. https:\/\/doi.org\/10.1096\/fj.04-3010fje","journal-title":"FASEB J"},{"issue":"8","key":"6021_CR196","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1007\/s12035-019-1495-4","volume":"56","author":"E Martinez-Pinilla","year":"2019","unstructured":"Martinez-Pinilla E, Aguinaga D, Navarro G, Rico AJ, Oyarzabal J, Sanchez-Arias JA, Lanciego JL, Franco R (2019) Targeting CB(1) and GPR55 endocannabinoid receptors as a potential neuroprotective approach for Parkinson\u2019s disease. Mol Neurobiol 56(8):5900\u20135910. https:\/\/doi.org\/10.1007\/s12035-019-1495-4","journal-title":"Mol Neurobiol"},{"issue":"Pt A","key":"6021_CR197","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.expneurol.2016.06.014","volume":"283","author":"RM Concannon","year":"2016","unstructured":"Concannon RM, Okine BN, Finn DP, Dowd E (2016) Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson\u2019s disease. Exp Neurol 283(Pt A):204\u2013212. https:\/\/doi.org\/10.1016\/j.expneurol.2016.06.014","journal-title":"Exp Neurol"},{"key":"6021_CR198","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.expneurol.2015.04.007","volume":"269","author":"RM Concannon","year":"2015","unstructured":"Concannon RM, Okine BN, Finn DP, Dowd E (2015) Differential upregulation of the cannabinoid CB(2) receptor in neurotoxic and inflammation-driven rat models of Parkinson\u2019s disease. Exp Neurol 269:133\u2013141. https:\/\/doi.org\/10.1016\/j.expneurol.2015.04.007","journal-title":"Exp Neurol"},{"issue":"2","key":"6021_CR199","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s13311-018-0603-x","volume":"15","author":"F Navarrete","year":"2018","unstructured":"Navarrete F, Garcia-Gutierrez MS, Aracil-Fernandez A, Lanciego JL, Manzanares J (2018) Cannabinoid CB1 and CB2 receptors, and monoacylglycerol lipase gene expression alterations in the basal ganglia of patients with Parkinson\u2019s disease. Neurotherapeutics 15(2):459\u2013469. https:\/\/doi.org\/10.1007\/s13311-018-0603-x","journal-title":"Neurotherapeutics"},{"key":"6021_CR200","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.pnpbp.2015.03.017","volume":"64","author":"Y Gomez-Galvez","year":"2016","unstructured":"Gomez-Galvez Y, Palomo-Garo C, Fernandez-Ruiz J, Garcia C (2016) Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson\u2019s disease. Prog Neuropsychopharmacol Biol Psychiatry 64:200\u2013208. https:\/\/doi.org\/10.1016\/j.pnpbp.2015.03.017","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"6021_CR201","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.bbi.2025.04.037","volume":"128","author":"L Ayerra","year":"2025","unstructured":"Ayerra L, Abellanas MA, Vidaurre C, Basurco L, Tavira A, Luquin E, Clavero P, Mengual E et al (2025) Activation of central cannabinoid type 2 receptors, but not on peripheral immune cells, is required for endocannabinoid-mediated neuroprotection in Parkinson\u2019s disease. Brain Behav Immun 128:600\u2013611. https:\/\/doi.org\/10.1016\/j.bbi.2025.04.037","journal-title":"Brain Behav Immun"},{"key":"6021_CR202","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2016.00321","volume":"10","author":"H Javed","year":"2016","unstructured":"Javed H, Azimullah S, Haque ME, Ojha SK (2016) Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of Parkinson\u2019s disease. Front Neurosci 10:321. https:\/\/doi.org\/10.3389\/fnins.2016.00321","journal-title":"Front Neurosci"},{"key":"6021_CR203","doi-asserted-by":"publisher","unstructured":"Yu H, Liu X, Chen B, Vickstrom CR, Friedman V, Kelly TJ, Bai X, Zhao L et al (2021) The neuroprotective effects of the CB2 agonist GW842166x in the 6-OHDA mouse model of Parkinson\u2019s disease. Cells 10(12):3548. https:\/\/doi.org\/10.3390\/cells10123548","DOI":"10.3390\/cells10123548"},{"issue":"1","key":"6021_CR204","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12974-023-02989-2","volume":"20","author":"H Zhu","year":"2023","unstructured":"Zhu H, Xiao F, Xiao Y, Guo Y, Shan X, Zhang Z, Zhang L, Guo H (2023) Targeting CB2R in astrocytes for Parkinson\u2019s disease therapy: unraveling the Foxg1-mediated neuroprotective mechanism through autophagy-mediated NLRP3 degradation. J Neuroinflammation 20(1):304. https:\/\/doi.org\/10.1186\/s12974-023-02989-2","journal-title":"J Neuroinflammation"},{"issue":"1","key":"6021_CR205","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2015.100","volume":"48","author":"YC Chung","year":"2016","unstructured":"Chung YC, Shin WH, Baek JY, Cho EJ, Baik HH, Kim SR, Won SY, Jin BK (2016) CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson\u2019s disease. Exp Mol Med 48(1):e205. https:\/\/doi.org\/10.1038\/emm.2015.100","journal-title":"Exp Mol Med"},{"issue":"1","key":"6021_CR206","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03221-5","volume":"21","author":"V Joers","year":"2024","unstructured":"Joers V, Murray BC, McLaughlin C, Oliver D, Staley HE, Coronado J, Achat-Mendes C, Golshani S et al (2024) Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy. J Neuroinflammation 21(1):240. https:\/\/doi.org\/10.1186\/s12974-024-03221-5","journal-title":"J Neuroinflammation"},{"issue":"5","key":"6021_CR207","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1007\/s11033-023-08395-4","volume":"50","author":"M Wang","year":"2023","unstructured":"Wang M, Liu M, Ma Z (2023) Cannabinoid type 2 receptor activation inhibits MPP(+)-induced M1 differentiation of microglia through activating PI3K\/Akt\/Nrf2 signal pathway. Mol Biol Rep 50(5):4423\u20134433. https:\/\/doi.org\/10.1007\/s11033-023-08395-4","journal-title":"Mol Biol Rep"},{"issue":"3","key":"6021_CR208","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1152\/jn.00137.2024","volume":"132","author":"M Liu","year":"2024","unstructured":"Liu M, Pan D, Wang M, Deng H, Ma Z (2024) JWH133 attenuates behavior deficits and iron accumulation in 6-OHDA-induced Parkinson\u2019s disease model rats. J Neurophysiol 132(3):733\u2013743. https:\/\/doi.org\/10.1152\/jn.00137.2024","journal-title":"J Neurophysiol"},{"key":"6021_CR209","doi-asserted-by":"publisher","unstructured":"He X, Yang L, Huang R, Lin L, Shen Y, Cheng L, Jin L, Wang S et al (2020) Activation of CB2R with AM1241 ameliorates neurodegeneration via the Xist\/miR-133b-3p\/Pitx3 axis. J Cell Physiol 235(9):6032\u20136042. https:\/\/doi.org\/10.1002\/jcp.29530","DOI":"10.1002\/jcp.29530"},{"issue":"6","key":"6021_CR210","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/mds.10289","volume":"17","author":"SH Fox","year":"2002","unstructured":"Fox SH, Henry B, Hill M, Crossman A, Brotchie J (2002) Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson\u2019s disease. Mov Disord 17(6):1180\u20131187. https:\/\/doi.org\/10.1002\/mds.10289","journal-title":"Mov Disord"},{"key":"6021_CR211","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104646","volume":"134","author":"P Rentsch","year":"2020","unstructured":"Rentsch P, Stayte S, Egan T, Clark I, Vissel B (2020) Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia. Neurobiol Dis 134:104646. https:\/\/doi.org\/10.1016\/j.nbd.2019.104646","journal-title":"Neurobiol Dis"},{"key":"6021_CR212","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.phrs.2016.04.004","volume":"110","author":"C Palomo-Garo","year":"2016","unstructured":"Palomo-Garo C, Gomez-Galvez Y, Garcia C, Fernandez-Ruiz J (2016) Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice. Pharmacol Res 110:181\u2013192. https:\/\/doi.org\/10.1016\/j.phrs.2016.04.004","journal-title":"Pharmacol Res"},{"key":"6021_CR213","doi-asserted-by":"publisher","unstructured":"Corkrum M, Covelo A, Lines J, Bellocchio L, Pisansky M, Loke K, Quintana R, Rothwell PE et al (2020) Dopamine-evoked synaptic regulation in the nucleus accumbens requires astrocyte activity. Neuron 105(6):1036-1047 e1035. https:\/\/doi.org\/10.1016\/j.neuron.2019.12.026","DOI":"10.1016\/j.neuron.2019.12.026"},{"key":"6021_CR214","doi-asserted-by":"publisher","unstructured":"Mishina M, Ishii K, Kimura Y, Suzuki M, Kitamura S, Ishibashi K, Sakata M, Oda K et al (2017) Adenosine A(1) receptors measured with (11) C-MPDX PET in early Parkinson\u2019s disease. Synapse. https:\/\/doi.org\/10.1002\/syn.21979","DOI":"10.1002\/syn.21979"},{"issue":"2","key":"6021_CR215","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s11307-017-1116-4","volume":"20","author":"D Nabbi-Schroeter","year":"2018","unstructured":"Nabbi-Schroeter D, Elmenhorst D, Oskamp A, Laskowski S, Bauer A, Kroll T (2018) Effects of long-term caffeine consumption on the adenosine A(1) receptor in the rat brain: an in vivo PET study with [(18)F]CPFPX. Mol Imaging Biol 20(2):284\u2013291. https:\/\/doi.org\/10.1007\/s11307-017-1116-4","journal-title":"Mol Imaging Biol"},{"key":"6021_CR216","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.expneurol.2014.08.022","volume":"261","author":"D Mango","year":"2014","unstructured":"Mango D, Bonito-Oliva A, Ledonne A, Cappellacci L, Petrelli R, Nistico R, Berretta N, Fisone G et al (2014) Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice. Exp Neurol 261:733\u2013743. https:\/\/doi.org\/10.1016\/j.expneurol.2014.08.022","journal-title":"Exp Neurol"},{"issue":"3","key":"6021_CR217","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/sj.bjp.0706732","volume":"148","author":"HQ Liu","year":"2006","unstructured":"Liu HQ, Zhang WY, Luo XT, Ye Y, Zhu XZ (2006) Paeoniflorin attenuates neuroinflammation and dopaminergic neurodegeneration in the MPTP model of Parkinson\u2019s disease by activation of adenosine A1 receptor. Br J Pharmacol 148(3):314\u2013325. https:\/\/doi.org\/10.1038\/sj.bjp.0706732","journal-title":"Br J Pharmacol"},{"issue":"1","key":"6021_CR218","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40035-022-00284-3","volume":"11","author":"E Jakova","year":"2022","unstructured":"Jakova E, Moutaoufik MT, Lee JS, Babu M, Cayabyab FS (2022) Adenosine A1 receptor ligands bind to alpha-synuclein: implications for alpha-synuclein misfolding and alpha-synucleinopathy in Parkinson\u2019s disease. Transl Neurodegener 11(1):9. https:\/\/doi.org\/10.1186\/s40035-022-00284-3","journal-title":"Transl Neurodegener"},{"issue":"1","key":"6021_CR219","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s00415-022-11342-1","volume":"270","author":"I Waggan","year":"2023","unstructured":"Waggan I, Rissanen E, Tuisku J, Joutsa J, Helin S, Parkkola R, Rinne JO, Airas L (2023) Adenosine A(2A) receptor availability in patients with early- and moderate-stage Parkinson\u2019s disease. J Neurol 270(1):300\u2013310. https:\/\/doi.org\/10.1007\/s00415-022-11342-1","journal-title":"J Neurol"},{"key":"6021_CR220","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105766","volume":"113","author":"I Waggan","year":"2023","unstructured":"Waggan I, Rissanen E, Tuisku J, Matilainen M, Parkkola R, Rinne JO, Airas L (2023) Adenosine A(2A) receptor availability in cerebral gray and white matter of patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 113:105766. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105766","journal-title":"Parkinsonism Relat Disord"},{"issue":"18","key":"6021_CR221","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1111\/bph.14771","volume":"176","author":"M Carmo","year":"2019","unstructured":"Carmo M, Goncalves FQ, Canas PM, Oses JP, Fernandes FD, Duarte FV, Palmeira CM, Tome AR et al (2019) Enhanced ATP release and CD73\u2010mediated adenosine formation sustain adenosine A2A receptor over\u2010activation in a rat model of Parkinson\u2019s disease. Br J Pharmacol 176(18):3666\u20133680. https:\/\/doi.org\/10.1111\/bph.14771","journal-title":"Br J Pharmacol"},{"key":"6021_CR222","doi-asserted-by":"publisher","unstructured":"Goncalves FQ, Matheus FC, Silva HB, Real JI, Rial D, Rodrigues RJ, Oses JP, Silva AC et al (2023) Increased ATP release and higher impact of adenosine A(2A) receptors on corticostriatal plasticity in a rat model of presymptomatic Parkinson\u2019s disease. Mol Neurobiol 60(3):1659\u20131674. https:\/\/doi.org\/10.1007\/s12035-022-03162-1","DOI":"10.1007\/s12035-022-03162-1"},{"issue":"Pt 5","key":"6021_CR223","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/brain\/awh128","volume":"127","author":"F Calon","year":"2004","unstructured":"Calon F, Dridi M, Hornykiewicz O, Bedard PJ, Rajput AH, Di Paolo T (2004) Increased adenosine A2A receptors in the brain of Parkinson\u2019s disease patients with dyskinesias. Brain 127(Pt 5):1075\u20131084. https:\/\/doi.org\/10.1093\/brain\/awh128","journal-title":"Brain"},{"key":"6021_CR224","doi-asserted-by":"publisher","unstructured":"Varani K, Vincenzi F, Tosi A, Gessi S, Casetta I, Granieri G, Fazio P, Leung E et al (2010) A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson\u2019s disease. FASEB J 24(2):587\u2013598. https:\/\/doi.org\/10.1096\/fj.09-141044","DOI":"10.1096\/fj.09-141044"},{"key":"6021_CR225","doi-asserted-by":"publisher","unstructured":"Li Z, Chen X, Wang T, Gao Y, Li F, Chen L, Xue J, He Y et al (2018) The Corticostriatal Adenosine A(2A) Receptor controls maintenance and retrieval of spatial working memory. Biol Psychiatry 83(6):530\u2013541. https:\/\/doi.org\/10.1016\/j.biopsych.2017.07.017","DOI":"10.1016\/j.biopsych.2017.07.017"},{"key":"6021_CR226","doi-asserted-by":"publisher","unstructured":"Yu L, Shen HY, Coelho JE, Araujo IM, Huang QY, Day YJ, Rebola N, Canas PM et al (2008) Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol 63(3):338\u2013346. https:\/\/doi.org\/10.1002\/ana.21313","DOI":"10.1002\/ana.21313"},{"key":"6021_CR227","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2023.137610","volume":"826","author":"Q Hu","year":"2024","unstructured":"Hu Q, Xu L, Liu X, Wang Y, Yuan J (2024) Adenosine A(2A) receptor antagonist KW6002 protects against A53T mutant alpha-synuclein-induced brain damage and neuronal apoptosis in Parkinson\u2019s disease mice by restoring autophagic flux. Neurosci Lett 826:137610. https:\/\/doi.org\/10.1016\/j.neulet.2023.137610","journal-title":"Neurosci Lett"},{"key":"6021_CR228","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.110278","volume":"266","author":"S Khanal","year":"2025","unstructured":"Khanal S, Shin EJ, Yoo CJ, Kim J, Choi DY (2025) Inosine exerts dopaminergic neuroprotective effects via mitigation of NLRP3 inflammasome activation. Neuropharmacology 266:110278. https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110278","journal-title":"Neuropharmacology"},{"key":"6021_CR229","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2025.128077","volume":"293","author":"W Zhu","year":"2025","unstructured":"Zhu W, Hu Y, Shi Y, Bao H, Cheng X, Jiang M, Peng Z, Song J et al (2025) Sleep deprivation accelerates Parkinson\u2019s disease via modulating gut microbiota associated microglial activation and oxidative stress. Microbiol Res 293:128077. https:\/\/doi.org\/10.1016\/j.micres.2025.128077","journal-title":"Microbiol Res"},{"key":"6021_CR230","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109652","volume":"238","author":"S Khanal","year":"2023","unstructured":"Khanal S, Bok E, Kim J, Park GH, Choi DY (2023) Dopaminergic neuroprotective effects of inosine in MPTP-induced parkinsonian mice via brain-derived neurotrophic factor upregulation. Neuropharmacology 238:109652. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109652","journal-title":"Neuropharmacology"},{"key":"6021_CR231","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.neuropharm.2018.09.036","volume":"143","author":"K Ishibashi","year":"2018","unstructured":"Ishibashi K, Miura Y, Wagatsuma K, Toyohara J, Ishiwata K, Ishii K (2018) Occupancy of adenosine A(2A) receptors by istradefylline in patients with Parkinson\u2019s disease using (11)C-preladenant PET. Neuropharmacology 143:106\u2013112. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.09.036","journal-title":"Neuropharmacology"},{"issue":"3","key":"6021_CR232","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ana.21315","volume":"63","author":"PA LeWitt","year":"2008","unstructured":"LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, Sussman NM, Group USS (2008) Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces \u201coff\u201d time in Parkinson\u2019s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 63(3):295\u2013302. https:\/\/doi.org\/10.1002\/ana.21315","journal-title":"Ann Neurol"},{"issue":"2","key":"6021_CR233","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.nbd.2010.07.008","volume":"40","author":"D Marcellino","year":"2010","unstructured":"Marcellino D, Lindqvist E, Schneider M, Muller CE, Fuxe K, Olson L, Galter D (2010) Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice. Neurobiol Dis 40(2):460\u2013466. https:\/\/doi.org\/10.1016\/j.nbd.2010.07.008","journal-title":"Neurobiol Dis"},{"issue":"6","key":"6021_CR234","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.1007\/s11030-025-11120-x","volume":"29","author":"A Singh","year":"2025","unstructured":"Singh A, Prakash A, Mishra J, Luthra PM (2025) Discovery of novel A(2A)R antagonist via 3D-QSAR pharmacophore modeling: neuroprotective effects in 6-OHDA-induced SH-SY5Y cells and haloperidol-induced Parkinsonism in C57 bl\/6 mice. Mol Divers 29(6):5925\u20135953. https:\/\/doi.org\/10.1007\/s11030-025-11120-x","journal-title":"Mol Divers"},{"key":"6021_CR235","doi-asserted-by":"publisher","unstructured":"Sun B, Bachhawat P, Chu ML, Wood M, Ceska T, Sands ZA, Mercier J, Lebon F et al (2017) Crystal structure of the adenosine A(2A) receptor bound to an antagonist reveals a potential allosteric pocket. Proc Natl Acad Sci U S A 114(8):2066\u20132071. https:\/\/doi.org\/10.1073\/pnas.1621423114","DOI":"10.1073\/pnas.1621423114"},{"issue":"7","key":"6021_CR236","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.4103\/NRR.NRR-D-23-01542","volume":"20","author":"MZ Jovanovic","year":"2025","unstructured":"Jovanovic MZ, Stanojevic J, Stevanovic I, Ninkovic M, Ilic TV, Nedeljkovic N, Dragic M (2025) Prolonged intermittent theta burst stimulation restores the balance between A2AR- and A1R-mediated adenosine signaling in the 6-hydroxidopamine model of Parkinson\u2019s disease. Neural Regen Res 20(7):2053\u20132067. https:\/\/doi.org\/10.4103\/NRR.NRR-D-23-01542","journal-title":"Neural Regen Res"},{"key":"6021_CR237","doi-asserted-by":"publisher","unstructured":"Sarasola LI, Del Torrent CL, Perez-Arevalo A, Argerich J, Casajuana-Martin N, Chevigne A, Fernandez-Duenas V, Ferre S et al (2022) The ADORA1 mutation linked to early-onset Parkinson\u2019s disease alters adenosine A(1)-A(2A) receptor heteromer formation and function. Biomed Pharmacother 156:113896. https:\/\/doi.org\/10.1016\/j.biopha.2022.113896","DOI":"10.1016\/j.biopha.2022.113896"},{"key":"6021_CR238","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143600","author":"V Fernandez-Duenas","year":"2019","unstructured":"Fernandez-Duenas V, Gomez-Soler M, Valle-Leon M, Watanabe M, Ferrer I, Ciruela F (2019) Revealing adenosine A(2A)-dopamine D(2) receptor heteromers in Parkinson\u2019s disease post-mortem brain through a new alphascreen-based assay. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20143600","journal-title":"Int J Mol Sci"},{"key":"6021_CR239","doi-asserted-by":"publisher","unstructured":"Rivas-Santisteban R, Rico AJ, Munoz A, Rodriguez-Perez AI, Reyes-Resina I, Navarro G, Labandeira-Garcia JL, Lanciego JL et al (2023) Boolean analysis shows a high proportion of dopamine D(2) receptors interacting with adenosine A(2A) receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson\u2019s disease. Neurobiol Dis 188:106341. https:\/\/doi.org\/10.1016\/j.nbd.2023.106341","DOI":"10.1016\/j.nbd.2023.106341"},{"key":"6021_CR240","doi-asserted-by":"publisher","unstructured":"Herve D, Le Moine C, Corvol JC, Belluscio L, Ledent C, Fienberg AA, Jaber M, Studler JM et al (2001) Galpha(olf) levels are regulated by receptor usage and control dopamine and adenosine action in the striatum. J Neurosci 21(12):4390\u20134399. https:\/\/doi.org\/10.1523\/JNEUROSCI.21-12-04390.2001","DOI":"10.1523\/JNEUROSCI.21-12-04390.2001"},{"key":"6021_CR241","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.neuropharm.2019.01.014","volume":"148","author":"Q Wang","year":"2019","unstructured":"Wang Q, Zhou FM (2019) cAMP-producing chemogenetic and adenosine A2a receptor activation inhibits the inwardly rectifying potassium current in striatal projection neurons. Neuropharmacology 148:229\u2013243. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.01.014","journal-title":"Neuropharmacology"},{"issue":"15","key":"6021_CR242","doi-asserted-by":"publisher","first-page":"5848","DOI":"10.1523\/JNEUROSCI.20-15-05848.2000","volume":"20","author":"S Aoyama","year":"2000","unstructured":"Aoyama S, Kase H, Borrelli E (2000) Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci 20(15):5848\u20135852. https:\/\/doi.org\/10.1523\/JNEUROSCI.20-15-05848.2000","journal-title":"J Neurosci"},{"key":"6021_CR243","doi-asserted-by":"publisher","unstructured":"Romero-Fernandez W, Taura JJ, Crans RAJ, Lopez-Cano M, Fores-Pons R, Narvaez M, Carlsson J, Ciruela F et al (2022) The mGlu(5) Receptor Protomer-Mediated Dopamine D(2) receptor trans-inhibition is dependent on the adenosine A(2A) receptor protomer: implications for Parkinson\u2019s disease. Mol Neurobiol 59(10):5955\u20135969. https:\/\/doi.org\/10.1007\/s12035-022-02946-9","DOI":"10.1007\/s12035-022-02946-9"},{"key":"6021_CR244","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-2-1","volume":"2","author":"TN Grammatopoulos","year":"2007","unstructured":"Grammatopoulos TN, Jones SM, Ahmadi FA, Hoover BR, Snell LD, Skoch J, Jhaveri VV, Poczobutt AM et al (2007) Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol Neurodegener 2:1. https:\/\/doi.org\/10.1186\/1750-1326-2-1","journal-title":"Mol Neurodegener"},{"issue":"2","key":"6021_CR245","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/j.1471-4159.2009.05999.x","volume":"109","author":"B Joglar","year":"2009","unstructured":"Joglar B, Rodriguez-Pallares J, Rodriguez-Perez AI, Rey P, Guerra MJ, Labandeira-Garcia JL (2009) The inflammatory response in the MPTP model of Parkinson\u2019s disease is mediated by brain angiotensin: relevance to progression of the disease. J Neurochem 109(2):656\u2013669. https:\/\/doi.org\/10.1111\/j.1471-4159.2009.05999.x","journal-title":"J Neurochem"},{"issue":"1","key":"6021_CR246","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/glia.22595","volume":"62","author":"A Borrajo","year":"2014","unstructured":"Borrajo A, Rodriguez-Perez AI, Diaz-Ruiz C, Guerra MJ, Labandeira-Garcia JL (2014) Microglial TNF-alpha mediates enhancement of dopaminergic degeneration by brain angiotensin. Glia 62(1):145\u2013157. https:\/\/doi.org\/10.1002\/glia.22595","journal-title":"Glia"},{"key":"6021_CR247","doi-asserted-by":"publisher","first-page":"1457459","DOI":"10.3389\/fimmu.2024.1457459","volume":"15","author":"L Lage","year":"2024","unstructured":"Lage L, Rodriguez-Perez AI, Labandeira-Garcia JL, Dominguez-Meijide A (2024) Angiotensin type-1 receptor autoantibodies promote alpha-synuclein aggregation in dopaminergic neurons. Front Immunol 15:1457459. https:\/\/doi.org\/10.3389\/fimmu.2024.1457459","journal-title":"Front Immunol"},{"issue":"1","key":"6021_CR248","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41531-024-00650-0","volume":"10","author":"L Lage","year":"2024","unstructured":"Lage L, Rodriguez-Perez AI, Villar-Cheda B, Labandeira-Garcia JL, Dominguez-Meijide A (2024) Angiotensin type 1 receptor activation promotes neuronal and glial alpha-synuclein aggregation and transmission. NPJ Parkinsons Dis 10(1):37. https:\/\/doi.org\/10.1038\/s41531-024-00650-0","journal-title":"NPJ Parkinsons Dis"},{"key":"6021_CR249","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1742-2094-9-38","volume":"9","author":"P Garrido-Gil","year":"2012","unstructured":"Garrido-Gil P, Joglar B, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL (2012) Involvement of PPAR-gamma in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson\u2019s disease. J Neuroinflammation 9:38. https:\/\/doi.org\/10.1186\/1742-2094-9-38","journal-title":"J Neuroinflammation"},{"key":"6021_CR250","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.neuropharm.2013.05.025","volume":"73","author":"S Sathiya","year":"2013","unstructured":"Sathiya S, Ranju V, Kalaivani P, Priya RJ, Sumathy H, Sunil AG, Babu CS (2013) Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of alpha-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL\/6J mice. Neuropharmacology 73:98\u2013110. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.05.025","journal-title":"Neuropharmacology"},{"issue":"4","key":"6021_CR251","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s13311-018-0646-z","volume":"15","author":"AI Rodriguez-Perez","year":"2018","unstructured":"Rodriguez-Perez AI, Sucunza D, Pedrosa MA, Garrido-Gil P, Kulisevsky J, Lanciego JL, Labandeira-Garcia JL (2018) Angiotensin type 1 receptor antagonists protect against alpha-synuclein-induced neuroinflammation and dopaminergic neuron death. Neurotherapeutics 15(4):1063\u20131081. https:\/\/doi.org\/10.1007\/s13311-018-0646-z","journal-title":"Neurotherapeutics"},{"key":"6021_CR252","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11020329","author":"A Quijano","year":"2022","unstructured":"Quijano A, Diaz-Ruiz C, Lopez-Lopez A, Villar-Cheda B, Munoz A, Rodriguez-Perez AI, Labandeira-Garcia JL (2022) Angiotensin type-1 receptor inhibition reduces NLRP3 inflammasome upregulation induced by aging and neurodegeneration in the substantia nigra of male rodents and primary mesencephalic cultures. Antioxidants (Basel). https:\/\/doi.org\/10.3390\/antiox11020329","journal-title":"Antioxidants (Basel)"},{"key":"6021_CR253","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.expneurol.2014.08.019","volume":"261","author":"A Munoz","year":"2014","unstructured":"Munoz A, Garrido-Gil P, Dominguez-Meijide A, Labandeira-Garcia JL (2014) Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson\u2019s disease. Involvement of vascular endothelial growth factor and interleukin-1beta. Exp Neurol 261:720\u2013732. https:\/\/doi.org\/10.1016\/j.expneurol.2014.08.019","journal-title":"Exp Neurol"},{"issue":"6","key":"6021_CR254","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/antiox14060706","volume":"14","author":"CM Labandeira","year":"2025","unstructured":"Labandeira CM, Camacho-Meno L, Aracil-Pastor P, Suarez-Quintanilla JA, Labandeira-Garcia JL, Rodriguez-Perez AI (2025) Renin-angiotensin system autoantibody network in Parkinson\u2019s disease patients. Antioxidants (Basel) 14(6):706. https:\/\/doi.org\/10.3390\/antiox14060706","journal-title":"Antioxidants (Basel)"},{"issue":"1","key":"6021_CR255","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00340-9","volume":"8","author":"CM Labandeira","year":"2022","unstructured":"Labandeira CM, Pedrosa MA, Quijano A, Valenzuela R, Garrido-Gil P, Sanchez-Andrade M, Suarez-Quintanilla JA, Rodriguez-Perez AI et al (2022) Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson\u2019s disease. NPJ Parkinsons Dis 8(1):76. https:\/\/doi.org\/10.1038\/s41531-022-00340-9","journal-title":"NPJ Parkinsons Dis"},{"issue":"12","key":"6021_CR256","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.4103\/1673-5374.313061","volume":"16","author":"E Contaldi","year":"2021","unstructured":"Contaldi E, Magistrelli L, Milner AV, Cosentino M, Marino F, Comi C (2021) Potential protective role of ACE-inhibitors and AT1 receptor blockers against levodopa-induced dyskinesias: a retrospective case-control study. Neural Regen Res 16(12):2475\u20132478. https:\/\/doi.org\/10.4103\/1673-5374.313061","journal-title":"Neural Regen Res"},{"key":"6021_CR257","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.neuropharm.2013.07.016","volume":"76","author":"A Dominguez-Meijide","year":"2014","unstructured":"Dominguez-Meijide A, Villar-Cheda B, Garrido-Gil P, Sierrra-Paredes G, Guerra MJ, Labandeira-Garcia JL (2014) Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson\u2019s disease treated with L-DOPA. Neuropharmacology 76:156\u2013168. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.07.016","journal-title":"Neuropharmacology"},{"key":"6021_CR258","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ntt.2014.11.004","volume":"47","author":"J Lu","year":"2015","unstructured":"Lu J, Wu L, Jiang T, Wang Y, Zhao H, Gao Q, Pan Y, Tian Y et al (2015) Angiotensin AT2 receptor stimulation inhibits activation of NADPH oxidase and ameliorates oxidative stress in rotenone model of Parkinson\u2019s disease in CATH.a cells. Neurotoxicol Teratol 47:16\u201324. https:\/\/doi.org\/10.1016\/j.ntt.2014.11.004","journal-title":"Neurotoxicol Teratol"},{"issue":"5","key":"6021_CR259","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.4103\/1673-5374.324854","volume":"17","author":"Q Gao","year":"2022","unstructured":"Gao Q, Chen R, Wu L, Huang Q, Wang XX, Tian YY, Zhang YD (2022) Angiotensin-(1\u20137) reduces alpha-synuclein aggregation by enhancing autophagic activity in Parkinson\u2019s disease. Neural Regen Res 17(5):1138\u20131145. https:\/\/doi.org\/10.4103\/1673-5374.324854","journal-title":"Neural Regen Res"},{"issue":"10","key":"6021_CR260","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1021\/acschemneuro.1c00797","volume":"13","author":"S Gupta","year":"2022","unstructured":"Gupta S, Tiwari V, Tiwari P, Parul MA, Hanif K, Shukla S (2022) Angiotensin-converting enzyme 2 activation mitigates behavioral deficits and neuroinflammatory burden in 6-OHDA induced experimental models of Parkinson\u2019s disease. ACS Chem Neurosci 13(10):1491\u20131504. https:\/\/doi.org\/10.1021\/acschemneuro.1c00797","journal-title":"ACS Chem Neurosci"},{"key":"6021_CR261","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.bcp.2018.01.047","volume":"151","author":"MA Rabie","year":"2018","unstructured":"Rabie MA, Abd El Fattah MA, Nassar NN, El-Abhar HS, Abdallah DM (2018) Angiotensin 1\u20137 ameliorates 6-hydroxydopamine lesions in hemiparkinsonian rats through activation of MAS receptor\/PI3K\/Akt\/BDNF pathway and inhibition of angiotensin II type-1 receptor\/NF-kappaB axis. Biochem Pharmacol 151:126\u2013134. https:\/\/doi.org\/10.1016\/j.bcp.2018.01.047","journal-title":"Biochem Pharmacol"},{"key":"6021_CR262","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.113681","volume":"171","author":"MA Rabie","year":"2020","unstructured":"Rabie MA, Abd El Fattah MA, Nassar NN, Abdallah DM, El-Abhar HS (2020) Correlation between angiotensin 1\u20137-mediated Mas receptor expression with motor improvement, activated STAT3\/SOCS3 cascade, and suppressed HMGB-1\/RAGE\/NF-kappaB signaling in 6-hydroxydopamine hemiparkinsonian rats. Biochem Pharmacol 171:113681. https:\/\/doi.org\/10.1016\/j.bcp.2019.113681","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"6021_CR263","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.14336\/AD.2024.0981","volume":"16","author":"A Quijano","year":"2024","unstructured":"Quijano A, Rodriguez-Perez AI, Costa-Besada MA, Lopez-Lopez A, Guerra MJ, Labandeira-Garcia JL, Valenzuela R (2024) Modulation of mitochondrial dynamics by the angiotensin system in dopaminergic neurons and microglia. Aging Dis 16(5):3180\u20133203. https:\/\/doi.org\/10.14336\/AD.2024.0981","journal-title":"Aging Dis"},{"issue":"7","key":"6021_CR264","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.1007\/s12035-017-0805-y","volume":"55","author":"MA Costa-Besada","year":"2018","unstructured":"Costa-Besada MA, Valenzuela R, Garrido-Gil P, Villar-Cheda B, Parga JA, Lanciego JL, Labandeira-Garcia JL (2018) Paracrine and intracrine angiotensin 1\u20137\/Mas receptor axis in the substantia nigra of rodents, monkeys, and humans. Mol Neurobiol 55(7):5847\u20135867. https:\/\/doi.org\/10.1007\/s12035-017-0805-y","journal-title":"Mol Neurobiol"},{"issue":"1","key":"6021_CR265","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12974-020-01908-z","volume":"17","author":"R Rivas-Santisteban","year":"2020","unstructured":"Rivas-Santisteban R, Rodriguez-Perez AI, Munoz A, Reyes-Resina I, Labandeira-Garcia JL, Navarro G, Franco R (2020) Angiotensin AT(1) and AT(2) receptor heteromer expression in the hemilesioned rat model of Parkinson\u2019s disease that increases with levodopa-induced dyskinesia. J Neuroinflammation 17(1):243. https:\/\/doi.org\/10.1186\/s12974-020-01908-z","journal-title":"J Neuroinflammation"},{"issue":"2","key":"6021_CR266","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1007\/s13311-020-00986-4","volume":"18","author":"R Rivas-Santisteban","year":"2021","unstructured":"Rivas-Santisteban R, Lillo J, Munoz A, Rodriguez-Perez AI, Labandeira-Garcia JL, Navarro G, Franco R (2021) Novel interactions involving the mas receptor show potential of the renin-angiotensin system in the regulation of microglia activation: altered expression in parkinsonism and dyskinesia. Neurotherapeutics 18(2):998\u20131016. https:\/\/doi.org\/10.1007\/s13311-020-00986-4","journal-title":"Neurotherapeutics"},{"issue":"1","key":"6021_CR267","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41531-025-01213-7","volume":"11","author":"G Bastioli","year":"2025","unstructured":"Bastioli G, Mancini M, Patel JC, Gamallo-Lana B, Arnold JC, Mar AC, Rice ME (2025) Voluntary exercise increases striatal dopamine release and improves motor performance in aging mice. NPJ Parkinsons Dis 11(1):345. https:\/\/doi.org\/10.1038\/s41531-025-01213-7","journal-title":"NPJ Parkinsons Dis"},{"key":"6021_CR268","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.nbd.2013.11.017","volume":"63","author":"WA Toy","year":"2014","unstructured":"Toy WA, Petzinger GM, Leyshon BJ, Akopian GK, Walsh JP, Hoffman MV, Vuckovic MG, Jakowec MW (2014) Treadmill exercise reverses dendritic spine loss in direct and indirect striatal medium spiny neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson\u2019s disease. Neurobiol Dis 63:201\u2013209. https:\/\/doi.org\/10.1016\/j.nbd.2013.11.017","journal-title":"Neurobiol Dis"},{"issue":"2","key":"6021_CR269","doi-asserted-by":"publisher","first-page":"124","DOI":"10.12965\/jer.1734966.483","volume":"13","author":"MS Shin","year":"2017","unstructured":"Shin MS, Kim TW, Lee JM, Sung YH, Lim BV (2017) Treadmill exercise alleviates depressive symptoms in rotenone-induced Parkinson disease rats. J Exerc Rehabil 13(2):124\u2013129. https:\/\/doi.org\/10.12965\/jer.1734966.483","journal-title":"J Exerc Rehabil"},{"key":"6021_CR270","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3389\/fnagi.2019.00255","volume":"11","author":"P Chen","year":"2019","unstructured":"Chen P, Li X (2019) Study on effect of striatal mGluR2\/3 in alleviating motor dysfunction in rat PD model treated by exercise therapy. Front Aging Neurosci 11:255. https:\/\/doi.org\/10.3389\/fnagi.2019.00255","journal-title":"Front Aging Neurosci"},{"key":"6021_CR271","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neulet.2019.04.052","volume":"705","author":"K Shi","year":"2019","unstructured":"Shi K, Liu X, Hou L, Qiao D, Lin X (2019) Effects of exercise on mGluR-mediated glutamatergic transmission in the striatum of hemiparkinsonian rats. Neurosci Lett 705:143\u2013150. https:\/\/doi.org\/10.1016\/j.neulet.2019.04.052","journal-title":"Neurosci Lett"},{"issue":"4","key":"6021_CR272","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1080\/00222895.2018.1505711","volume":"51","author":"S Modaberi","year":"2019","unstructured":"Modaberi S, Heysieattalab S, Shahbazi M, Naghdi N (2019) Combination effects of forced mild exercise and GABA(B) receptor agonist on spatial learning, memory, and motor activity in striatum lesion rats. J Mot Behav 51(4):438\u2013450. https:\/\/doi.org\/10.1080\/00222895.2018.1505711","journal-title":"J Mot Behav"},{"key":"6021_CR273","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2025.115289","volume":"391","author":"T Zikereya","year":"2025","unstructured":"Zikereya T, Liu C, Wei L, Wang Y, Zhang Z, Han C, Shi K, Chen W (2025) The cannabinoid receptor 1 mediates exercise-induced improvements of motor skill learning and performance in parkinsonian mouse. Exp Neurol 391:115289. https:\/\/doi.org\/10.1016\/j.expneurol.2025.115289","journal-title":"Exp Neurol"},{"issue":"8","key":"6021_CR274","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/sms.13705","volume":"30","author":"DD Ludtke","year":"2020","unstructured":"Ludtke DD, Siteneski A, Galassi TO, Buffon AC, Cidral-Filho FJ, Reed WR, Salgado ASI, Dos Santos ARS et al (2020) High-intensity swimming exercise reduces inflammatory pain in mice by activation of the endocannabinoid system. Scand J Med Sci Sports 30(8):1369\u20131378. https:\/\/doi.org\/10.1111\/sms.13705","journal-title":"Scand J Med Sci Sports"},{"key":"6021_CR275","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.bbr.2014.07.006","volume":"272","author":"PJ Clark","year":"2014","unstructured":"Clark PJ, Ghasem PR, Mika A, Day HE, Herrera JJ, Greenwood BN, Fleshner M (2014) Wheel running alters patterns of uncontrollable stress-induced cfos mRNA expression in rat dorsal striatum direct and indirect pathways: a possible role for plasticity in adenosine receptors. Behav Brain Res 272:252\u2013263. https:\/\/doi.org\/10.1016\/j.bbr.2014.07.006","journal-title":"Behav Brain Res"},{"issue":"2","key":"6021_CR276","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5114\/fn.2023.125120","volume":"61","author":"R Li","year":"2023","unstructured":"Li R, Jin S, He J, Peng Y, Wei L, Gu L (2023) Exercise attenuates neuronal degeneration in Parkinson\u2019s disease rat model by regulating the level of adenosine 2A receptor. Folia Neuropathol 61(2):217\u2013223. https:\/\/doi.org\/10.5114\/fn.2023.125120","journal-title":"Folia Neuropathol"},{"issue":"12","key":"6021_CR277","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/gerona\/gly072","volume":"73","author":"A Munoz","year":"2018","unstructured":"Munoz A, Correa CL, Lopez-Lopez A, Costa-Besada MA, Diaz-Ruiz C, Labandeira-Garcia JL (2018) Physical exercise improves aging-related changes in angiotensin, IGF-1, SIRT1, SIRT3, and VEGF in the substantia nigra. J Gerontol A Biol Sci Med Sci 73(12):1594\u20131601. https:\/\/doi.org\/10.1093\/gerona\/gly072","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"6021_CR278","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.neuroimage.2017.01.018","volume":"148","author":"LC Dang","year":"2017","unstructured":"Dang LC, Castrellon JJ, Perkins SF, Le NT, Cowan RL, Zald DH, Samanez-Larkin GR (2017) Reduced effects of age on dopamine D2 receptor levels in physically active adults. Neuroimage 148:123\u2013129. https:\/\/doi.org\/10.1016\/j.neuroimage.2017.01.018","journal-title":"Neuroimage"},{"key":"6021_CR279","doi-asserted-by":"publisher","unstructured":"Fisher BE, Li Q, Nacca A, Salem GJ, Song J, Yip J, Hui JS, Jakowec MW et al (2013) Treadmill exercise elevates striatal dopamine D2 receptor binding potential in patients with early Parkinson\u2019s disease. NeuroReport 24(10):509\u2013514. https:\/\/doi.org\/10.1097\/WNR.0b013e328361dc13","DOI":"10.1097\/WNR.0b013e328361dc13"},{"issue":"12","key":"6021_CR280","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/mds.27865","volume":"34","author":"MA Sacheli","year":"2019","unstructured":"Sacheli MA, Neva JL, Lakhani B, Murray DK, Vafai N, Shahinfard E, English C, McCormick S et al (2019) Exercise increases caudate dopamine release and ventral striatal activation in Parkinson\u2019s disease. Mov Disord 34(12):1891\u20131900. https:\/\/doi.org\/10.1002\/mds.27865","journal-title":"Mov Disord"},{"issue":"16","key":"6021_CR281","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1002\/mds.23407","volume":"25","author":"MG Vuckovic","year":"2010","unstructured":"Vuckovic MG, Li Q, Fisher B, Nacca A, Leahy RM, Walsh JP, Mukherjee J, Williams C et al (2010) Exercise elevates dopamine D2 receptor in a mouse model of Parkinson\u2019s disease: in vivo imaging with [(1)(8)F]fallypride. Mov Disord 25(16):2777\u20132784. https:\/\/doi.org\/10.1002\/mds.23407","journal-title":"Mov Disord"},{"key":"6021_CR282","doi-asserted-by":"publisher","first-page":"1001256","DOI":"10.3389\/fnagi.2022.1001256","volume":"14","author":"G Zhao","year":"2022","unstructured":"Zhao G, Zhang D, Qiao D, Liu X (2022) Exercise improves behavioral dysfunction and inhibits the spontaneous excitatory postsynaptic current of D2-medium spiny neurons. Front Aging Neurosci 14:1001256. https:\/\/doi.org\/10.3389\/fnagi.2022.1001256","journal-title":"Front Aging Neurosci"},{"key":"6021_CR283","doi-asserted-by":"publisher","first-page":"5859098","DOI":"10.1155\/2020\/5859098","volume":"2020","author":"EE Bauer","year":"2020","unstructured":"Bauer EE, Buhr TJ, Reed CH, Clark PJ (2020) Exercise-induced adaptations to the mouse striatal adenosine system. Neural Plast 2020:5859098. https:\/\/doi.org\/10.1155\/2020\/5859098","journal-title":"Neural Plast"},{"issue":"11","key":"6021_CR284","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1007\/s00221-021-06186-6","volume":"239","author":"Y Feng","year":"2021","unstructured":"Feng Y, Zhou S, Sun J (2021) Exercise increases striatal Glu reuptake and improves motor dysfunction in 6-OHDA-induced Parkinson\u2019s disease rats. Exp Brain Res 239(11):3277\u20133287. https:\/\/doi.org\/10.1007\/s00221-021-06186-6","journal-title":"Exp Brain Res"},{"issue":"3","key":"6021_CR285","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5114\/fn.2022.118794","volume":"60","author":"J Guo","year":"2022","unstructured":"Guo J, Yang J, Fu J, Tripathi A (2022) Exercise improves the body function and protects the neuronal injury in Parkinson\u2019s disease rats by activating calpain 1 and kallikrein 6. Folia Neuropathol 60(3):301\u2013307. https:\/\/doi.org\/10.5114\/fn.2022.118794","journal-title":"Folia Neuropathol"},{"key":"6021_CR286","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2025.115497","volume":"395","author":"S Venkatesh","year":"2025","unstructured":"Venkatesh S, Kinzonzi N, Galfano A, Shah A, Franks J, Holden H, McManus G, Lipari N et al (2025) Optimizing L-DOPA treatment through treadmill controlled exercise in a hemi-parkinsonian rat model. Exp Neurol 395:115497. https:\/\/doi.org\/10.1016\/j.expneurol.2025.115497","journal-title":"Exp Neurol"},{"issue":"5","key":"6021_CR287","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s12640-023-00651-6","volume":"41","author":"KH Binda","year":"2023","unstructured":"Binda KH, Chacur M, Martins DO (2023) Exercise improves orofacial pain and modifies neuropeptide expression in a rat model of Parkinson\u2019s disease. Neurotox Res 41(5):459\u2013470. https:\/\/doi.org\/10.1007\/s12640-023-00651-6","journal-title":"Neurotox Res"},{"key":"6021_CR288","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2019.146521","volume":"1727","author":"KH Binda","year":"2020","unstructured":"Binda KH, Real CC, Ferreira AFF, Britto LR, Chacur M (2020) Antinociceptive effects of treadmill exercise in a rat model of Parkinson\u2019s disease: the role of cannabinoid and opioid receptors. Brain Res 1727:146521. https:\/\/doi.org\/10.1016\/j.brainres.2019.146521","journal-title":"Brain Res"},{"issue":"1","key":"6021_CR289","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s12640-015-9566-4","volume":"29","author":"AS Aguiar Jr","year":"2016","unstructured":"Aguiar AS Jr, Lopes SC, Tristao FS, Rial D, de Oliveira G, da Cunha C, Raisman-Vozari R, Prediger RD (2016) Exercise improves cognitive impairment and dopamine metabolism in MPTP-treated mice. Neurotox Res 29(1):118\u2013125. https:\/\/doi.org\/10.1007\/s12640-015-9566-4","journal-title":"Neurotox Res"},{"key":"6021_CR290","doi-asserted-by":"publisher","DOI":"10.1016\/j.crneur.2022.100039","volume":"3","author":"W Zhuo","year":"2022","unstructured":"Zhuo W, Lundquist AJ, Donahue EK, Guo Y, Phillips D, Petzinger GM, Jakowec MW, Holschneider DP (2022) A mind in motion: exercise improves cognitive flexibility, impulsivity and alters dopamine receptor gene expression in a Parkinsonian rat model. Curr Res Neurobiol 3:100039. https:\/\/doi.org\/10.1016\/j.crneur.2022.100039","journal-title":"Curr Res Neurobiol"},{"issue":"3","key":"6021_CR291","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1124\/jpet.109.162701","volume":"332","author":"JA Przybyla","year":"2010","unstructured":"Przybyla JA, Watts VJ (2010) Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers. J Pharmacol Exp Ther 332(3):710\u2013719. https:\/\/doi.org\/10.1124\/jpet.109.162701","journal-title":"J Pharmacol Exp Ther"},{"issue":"35","key":"6021_CR292","doi-asserted-by":"publisher","first-page":"27346","DOI":"10.1074\/jbc.M110.115634","volume":"285","author":"G Navarro","year":"2010","unstructured":"Navarro G, Ferre S, Cordomi A, Moreno E, Mallol J, Casado V, Cortes A, Hoffmann H et al (2010) Interactions between intracellular domains as key determinants of the quaternary structure and function of receptor heteromers. J Biol Chem 285(35):27346\u201327359. https:\/\/doi.org\/10.1074\/jbc.M110.115634","journal-title":"J Biol Chem"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06021-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-06021-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06021-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:35:24Z","timestamp":1782434124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-026-06021-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":292,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["6021"],"URL":"https:\/\/doi.org\/10.1007\/s12035-026-06021-5","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"22 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"724"}}